OA18219A - Methods and compositions for HIV-related disorders. - Google Patents
Methods and compositions for HIV-related disorders. Download PDFInfo
- Publication number
- OA18219A OA18219A OA1201700016 OA18219A OA 18219 A OA18219 A OA 18219A OA 1201700016 OA1201700016 OA 1201700016 OA 18219 A OA18219 A OA 18219A
- Authority
- OA
- OAPI
- Prior art keywords
- pyrimidine
- chloro
- carboxylic acid
- use according
- composition according
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 44
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 title claims abstract 9
- 239000000203 mixture Substances 0.000 title claims description 107
- 239000003443 antiviral agent Substances 0.000 claims abstract description 97
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 49
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- 206010065040 AIDS dementia complex Diseases 0.000 claims abstract description 18
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 11
- 208000010385 Neurocognitive Disorders Diseases 0.000 claims abstract description 10
- 208000008581 Brain Disease Diseases 0.000 claims abstract description 8
- 206010014623 Encephalopathy Diseases 0.000 claims abstract description 8
- 206010014625 Encephalopathy Diseases 0.000 claims abstract description 8
- 206010069149 Minor cognitive motor disease Diseases 0.000 claims abstract description 6
- 206010028570 Myelopathy Diseases 0.000 claims abstract description 5
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims abstract description 5
- 206010034606 Peripheral neuropathy Diseases 0.000 claims abstract description 5
- 208000005987 Polymyositis Diseases 0.000 claims abstract description 5
- 206010061367 Spinal cord disease Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 244
- -1 (R)-sec-butoxy Chemical group 0.000 claims description 71
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 37
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 33
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 18
- 208000009025 Nervous System Disease Diseases 0.000 claims description 17
- 206010029305 Neurological disorder Diseases 0.000 claims description 17
- 102000033147 ERVK-25 Human genes 0.000 claims description 14
- 230000002708 enhancing Effects 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 230000004927 fusion Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 102100012080 CCR5 Human genes 0.000 claims description 10
- 101700043583 CCR5 Proteins 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 230000003042 antagnostic Effects 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 10
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 10
- MCGSCOLBFJQGHM-SCZZXKLOSA-N Abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 9
- 239000003623 enhancer Substances 0.000 claims description 9
- XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 8
- 229960000689 Nevirapine Drugs 0.000 claims description 8
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 8
- 229940108652 Videx Drugs 0.000 claims description 8
- 229940098802 Viramune Drugs 0.000 claims description 8
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 8
- 229960002656 didanosine Drugs 0.000 claims description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 230000000275 pharmacokinetic Effects 0.000 claims description 8
- 229940042402 Non-nucleoside reverse transcriptase inhibitors Drugs 0.000 claims description 7
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 claims description 7
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 7
- 239000002777 nucleoside Substances 0.000 claims description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- LCWISMLAGSYMOD-UHFFFAOYSA-N 6-(3,4-difluorophenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(F)C(F)=CC=2)=N1 LCWISMLAGSYMOD-UHFFFAOYSA-N 0.000 claims description 6
- JAJUIFDFFNEPOK-UHFFFAOYSA-N 6-(3-chloro-4-cyclobutyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CCC3)=CC=2)=N1 JAJUIFDFFNEPOK-UHFFFAOYSA-N 0.000 claims description 6
- MUQRMMDWZTUCAE-UHFFFAOYSA-N 6-(3-chloro-4-cyclopentyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CCCC3)=CC=2)=N1 MUQRMMDWZTUCAE-UHFFFAOYSA-N 0.000 claims description 6
- UPKQDTLLVVTZQT-UHFFFAOYSA-N 6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OC3CC3)=CC=2)=N1 UPKQDTLLVVTZQT-UHFFFAOYSA-N 0.000 claims description 6
- WWIJIMDOMQMPAS-UHFFFAOYSA-N 6-(3-chloro-4-propan-2-yloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=CC(C(O)=O)=NC=N1 WWIJIMDOMQMPAS-UHFFFAOYSA-N 0.000 claims description 6
- SIYCDJHEVASOGW-UHFFFAOYSA-N 6-(4-chloro-3-cyclopropyloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(OC3CC3)C(Cl)=CC=2)=N1 SIYCDJHEVASOGW-UHFFFAOYSA-N 0.000 claims description 6
- LNZXPHYFMZYUJV-UHFFFAOYSA-N 6-(4-chloro-3-fluorophenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(F)C(Cl)=CC=2)=N1 LNZXPHYFMZYUJV-UHFFFAOYSA-N 0.000 claims description 6
- KAPFCJYSHMMHHG-UHFFFAOYSA-N 6-(4-chloro-3-methoxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 KAPFCJYSHMMHHG-UHFFFAOYSA-N 0.000 claims description 6
- HAKPEXMHSQJZGE-UHFFFAOYSA-N 6-(4-chloro-3-propan-2-yloxyphenyl)pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 HAKPEXMHSQJZGE-UHFFFAOYSA-N 0.000 claims description 6
- NGFZWJQXSNGURC-UHFFFAOYSA-N 6-[3-chloro-4-(1-cyclopropyloxyethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C=1C=C(C=2N=CN=C(C=2)C(O)=O)C=C(Cl)C=1C(C)OC1CC1 NGFZWJQXSNGURC-UHFFFAOYSA-N 0.000 claims description 6
- YBGVQOWGBBFAAT-UHFFFAOYSA-N 6-[3-chloro-4-(cyclopropyloxymethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(COC3CC3)=CC=2)=N1 YBGVQOWGBBFAAT-UHFFFAOYSA-N 0.000 claims description 6
- PSOBNYRYPKZAFV-SECBINFHSA-N 6-[4-[(2R)-butan-2-yl]oxy-3-chlorophenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(O[C@H](C)CC)=CC=C1C1=CC(C(O)=O)=NC=N1 PSOBNYRYPKZAFV-SECBINFHSA-N 0.000 claims description 6
- 108010061833 Integrases Proteins 0.000 claims description 6
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 claims description 6
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 5
- FMCLRHTZMTUYMI-JFQFMQNHSA-N 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(E)-but-2-enedioic acid;6-[(3-chloro-2-fluorop Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N.S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 FMCLRHTZMTUYMI-JFQFMQNHSA-N 0.000 claims description 5
- FPVPSYCVUOIXCH-UHFFFAOYSA-N 6-(3,4-dichlorophenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(Cl)=CC=2)=N1 FPVPSYCVUOIXCH-UHFFFAOYSA-N 0.000 claims description 5
- BGDKIMDTKMFAFC-UHFFFAOYSA-N 6-(3-chloro-4-fluorophenyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(F)=CC=2)=N1 BGDKIMDTKMFAFC-UHFFFAOYSA-N 0.000 claims description 5
- NUJCWQZUTBHBHQ-UHFFFAOYSA-N 6-[3-chloro-4-(1-methoxyethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(C(C)OC)=CC=C1C1=CC(C(O)=O)=NC=N1 NUJCWQZUTBHBHQ-UHFFFAOYSA-N 0.000 claims description 5
- FHITUBQLEKRUQU-UHFFFAOYSA-N 6-[3-chloro-4-(cyclopropylmethoxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C=2C=C(Cl)C(OCC3CC3)=CC=2)=N1 FHITUBQLEKRUQU-UHFFFAOYSA-N 0.000 claims description 5
- GCKCDGAFVFDNGW-UHFFFAOYSA-N 6-[3-chloro-4-(methoxymethyl)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(COC)=CC=C1C1=CC(C(O)=O)=NC=N1 GCKCDGAFVFDNGW-UHFFFAOYSA-N 0.000 claims description 5
- PSOBNYRYPKZAFV-VIFPVBQESA-N 6-[4-[(2S)-butan-2-yl]oxy-3-chlorophenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(O[C@@H](C)CC)=CC=C1C1=CC(C(O)=O)=NC=N1 PSOBNYRYPKZAFV-VIFPVBQESA-N 0.000 claims description 5
- RHWKPHLQXYSBKR-BMIGLBTASA-N Dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 5
- XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 5
- JUZYLCPPVHEVSV-LJQANCHMSA-N Elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 claims description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 5
- 229940070590 Stribild Drugs 0.000 claims description 5
- 229960004748 abacavir Drugs 0.000 claims description 5
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 claims description 5
- 229960002402 cobicistat Drugs 0.000 claims description 5
- 229940000425 combination drugs Drugs 0.000 claims description 5
- 229960002542 dolutegravir Drugs 0.000 claims description 5
- 229960003804 efavirenz Drugs 0.000 claims description 5
- 229960003586 elvitegravir Drugs 0.000 claims description 5
- 230000035800 maturation Effects 0.000 claims description 5
- 229960002814 rilpivirine Drugs 0.000 claims description 5
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims description 5
- 229960000311 ritonavir Drugs 0.000 claims description 5
- PNDKCRDVVKJPKG-WHERJAGFSA-N (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 claims description 4
- SVUJNSGGPUCLQZ-FQQAACOVSA-N (E)-but-2-enedioic acid;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 claims description 4
- MCPUZZJBAHRIPO-UHFFFAOYSA-N 5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile Chemical compound CCC1=NN(CCO)C(CC)=C1OC1=CC(C#N)=CC(C#N)=C1 MCPUZZJBAHRIPO-UHFFFAOYSA-N 0.000 claims description 4
- 229950005846 Amdoxovir Drugs 0.000 claims description 4
- 229940030139 Aptivus Drugs 0.000 claims description 4
- AXRYRYVKAWYZBR-GASGPIRDSA-N Atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 4
- 229940068561 Atripla Drugs 0.000 claims description 4
- 229950011033 Cenicriviroc Drugs 0.000 claims description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 4
- 229940014461 Combivir Drugs 0.000 claims description 4
- 229940088900 Crixivan Drugs 0.000 claims description 4
- 229940084014 Edurant Drugs 0.000 claims description 4
- 229940001018 Emtriva Drugs 0.000 claims description 4
- 229940072253 Epivir Drugs 0.000 claims description 4
- 229940019131 Epzicom Drugs 0.000 claims description 4
- PYGWGZALEOIKDF-UHFFFAOYSA-N Etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 claims description 4
- MLBVMOWEQCZNCC-OEMFJLHTSA-N Fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 claims description 4
- 229940099052 Fuzeon Drugs 0.000 claims description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 4
- 229940115474 Intelence Drugs 0.000 claims description 4
- 102000000704 Interleukin-7 Human genes 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 229940100994 Interleukin-7 Drugs 0.000 claims description 4
- 229940088976 Invirase Drugs 0.000 claims description 4
- 229940111682 Isentress Drugs 0.000 claims description 4
- 229940112586 Kaletra Drugs 0.000 claims description 4
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 4
- 229950004188 Lersivirine Drugs 0.000 claims description 4
- 229940113354 Lexiva Drugs 0.000 claims description 4
- GSNHKUDZZFZSJB-QYOOZWMWSA-N Maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 4
- 229940072250 Norvir Drugs 0.000 claims description 4
- 229940072689 Plaquenil Drugs 0.000 claims description 4
- 229940068586 Prezista Drugs 0.000 claims description 4
- 229940087463 Proleukin Drugs 0.000 claims description 4
- 229960004742 Raltegravir Drugs 0.000 claims description 4
- CZFFBEXEKNGXKS-UHFFFAOYSA-N Raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 claims description 4
- WHBIGIKBNXZKFE-UHFFFAOYSA-N Rescriptor Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 4
- 229940063627 Rescriptor Drugs 0.000 claims description 4
- 229940064914 Retrovir Drugs 0.000 claims description 4
- 229940107904 Reyataz Drugs 0.000 claims description 4
- 229960001852 Saquinavir Drugs 0.000 claims description 4
- QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 4
- 229940031307 Selzentry Drugs 0.000 claims description 4
- 229960001203 Stavudine Drugs 0.000 claims description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 4
- 229940054565 Sustiva Drugs 0.000 claims description 4
- SUJUHGSWHZTSEU-FYBSXPHGSA-N Tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 claims description 4
- 229940014075 Tivicay Drugs 0.000 claims description 4
- YATVXQQJLKIPSI-VETFBQQWSA-N Trizivir Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 YATVXQQJLKIPSI-VETFBQQWSA-N 0.000 claims description 4
- 229940111527 Trizivir Drugs 0.000 claims description 4
- 229940008349 Truvada Drugs 0.000 claims description 4
- 229940023080 Viracept Drugs 0.000 claims description 4
- 229940109657 Viread Drugs 0.000 claims description 4
- 229940087450 Zerit Drugs 0.000 claims description 4
- 229940052255 Ziagen Drugs 0.000 claims description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 4
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 claims description 4
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 claims description 4
- 229960003277 atazanavir Drugs 0.000 claims description 4
- 229960005107 darunavir Drugs 0.000 claims description 4
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 4
- 229960005319 delavirdine Drugs 0.000 claims description 4
- 229960000366 emtricitabine Drugs 0.000 claims description 4
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims description 4
- 229960002062 enfuvirtide Drugs 0.000 claims description 4
- 229960002049 etravirine Drugs 0.000 claims description 4
- 239000003316 glycosidase inhibitor Substances 0.000 claims description 4
- 229960001936 indinavir Drugs 0.000 claims description 4
- 229960004710 maraviroc Drugs 0.000 claims description 4
- 229960000884 nelfinavir Drugs 0.000 claims description 4
- 230000035892 strand transfer Effects 0.000 claims description 4
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 claims description 4
- 229960001355 tenofovir disoproxil Drugs 0.000 claims description 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 4
- 229960000838 tipranavir Drugs 0.000 claims description 4
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-Ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 claims description 3
- JRPORKJOVJJRHR-UHFFFAOYSA-N 6-[4-chloro-3-(2-methylpropoxy)phenyl]pyrimidine-4-carboxylic acid Chemical compound C1=C(Cl)C(OCC(C)C)=CC(C=2N=CN=C(C=2)C(O)=O)=C1 JRPORKJOVJJRHR-UHFFFAOYSA-N 0.000 claims description 3
- 229940029487 Complera Drugs 0.000 claims description 3
- 229950010245 Ibalizumab Drugs 0.000 claims description 3
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims description 3
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims description 3
- 108010004953 ibalizumab Proteins 0.000 claims description 3
- 239000002850 integrase inhibitor Substances 0.000 claims description 3
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims description 3
- 125000005920 sec-butoxy group Chemical group 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 2
- 241000560067 HIV-1 group M Species 0.000 claims 1
- 108010033242 Kynurenine 3-Monooxygenase Proteins 0.000 abstract description 45
- 102100012023 KMO Human genes 0.000 abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 30
- 241000725303 Human immunodeficiency virus Species 0.000 description 78
- YGPSJZOEDVAXAB-UHFFFAOYSA-N Kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 32
- GJAWHXHKYYXBSV-UHFFFAOYSA-N Quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 210000004556 Brain Anatomy 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cells Anatomy 0.000 description 24
- 239000000126 substance Substances 0.000 description 23
- HCZHHEIFKROPDY-UHFFFAOYSA-N 4-hydroxyquinaldic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 21
- 239000000651 prodrug Substances 0.000 description 21
- 229940002612 prodrugs Drugs 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 20
- 210000001577 Neostriatum Anatomy 0.000 description 19
- 238000004166 bioassay Methods 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drugs Drugs 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 239000012131 assay buffer Substances 0.000 description 12
- 230000000051 modifying Effects 0.000 description 12
- 238000003419 tautomerization reaction Methods 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000004432 carbon atoms Chemical group C* 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000003169 Central Nervous System Anatomy 0.000 description 8
- 208000005721 HIV Infections Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000001684 chronic Effects 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 238000001690 micro-dialysis Methods 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 7
- 229960004063 Propylene glycol Drugs 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 125000004429 atoms Chemical group 0.000 description 7
- 201000009910 diseases by infectious agent Diseases 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000002335 preservative Effects 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 235000010356 sorbitol Nutrition 0.000 description 7
- 239000000600 sorbitol Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 206010014599 Encephalitis Diseases 0.000 description 6
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine zwitterion Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-Hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 description 5
- 210000001723 Extracellular Space Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 5
- 102000006639 indoleamine 2,3-dioxygenase family Human genes 0.000 description 5
- 108020004201 indoleamine 2,3-dioxygenase family Proteins 0.000 description 5
- 230000000813 microbial Effects 0.000 description 5
- 210000002569 neurons Anatomy 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 230000003612 virological Effects 0.000 description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-Hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 description 4
- 239000005995 Aluminium silicate Substances 0.000 description 4
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- NBSCHQHZLSJFNQ-GASJEMHNSA-N Glucose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 family Proteins 0.000 description 4
- 229940067606 Lecithin Drugs 0.000 description 4
- 241000282553 Macaca Species 0.000 description 4
- 210000002540 Macrophages Anatomy 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 229960004319 Trichloroacetic Acid Drugs 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000001149 cognitive Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000926 neurological Effects 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000000750 progressive Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- SHZLHGQAJLHUML-GYPPTRPKSA-N 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SHZLHGQAJLHUML-GYPPTRPKSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- 102000005447 EC 3.7.1.3 Human genes 0.000 description 3
- 108010031676 EC 3.7.1.3 Proteins 0.000 description 3
- 102100005993 G6PD Human genes 0.000 description 3
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 230000036740 Metabolism Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 210000003470 Mitochondria Anatomy 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000000640 hydroxylating Effects 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035786 metabolism Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 238000002552 multiple reaction monitoring Methods 0.000 description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002093 peripheral Effects 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 206010000807 Acute HIV infection Diseases 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infection Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000223205 Coccidioides immitis Species 0.000 description 2
- 208000008953 Cryptosporidiosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229960001031 Glucose Drugs 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 101710031171 IDO1 Proteins 0.000 description 2
- 102100008614 IDO1 Human genes 0.000 description 2
- 206010023076 Isosporiasis Diseases 0.000 description 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000000274 Microglia Anatomy 0.000 description 2
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 description 2
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010036807 Progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 Saccharin Drugs 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 229940005550 Sodium alginate Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 230000000840 anti-viral Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000003542 behavioural Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 210000003008 brain-resident macrophage Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000035569 catabolism Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 201000003486 coccidioidomycosis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000007336 cryptococcosis Diseases 0.000 description 2
- 201000008167 cystoisosporiasis Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000003492 excitotoxic Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 201000002563 histoplasmosis Diseases 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 201000008125 pain agnosia Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 230000003362 replicative Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 201000005485 toxoplasmosis Diseases 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- VKMGSWIFEHZQRS-NSHDSACASA-N (1R)-1-(3,4-dichlorophenyl)-2-(propan-2-ylamino)ethanol Chemical compound CC(C)NC[C@H](O)C1=CC=C(Cl)C(Cl)=C1 VKMGSWIFEHZQRS-NSHDSACASA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- SHXCUQHMQIBOAR-UHFFFAOYSA-N 1,2,3$l^{2}-dioxaborolane Chemical compound [B]1CCOO1 SHXCUQHMQIBOAR-UHFFFAOYSA-N 0.000 description 1
- NAYSGTXOWDUFAT-UHFFFAOYSA-N 1-(4-bromo-2-chlorophenyl)ethanol Chemical compound CC(O)C1=CC=C(Br)C=C1Cl NAYSGTXOWDUFAT-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 1H-pyridin-4-one Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-XGXNLDPDSA-N 2,3-dihydroxypropyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-Ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- QOWAMIUFBNBINS-UHFFFAOYSA-N 2-[6-[4,5-diethoxy-2-(ethoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(OC)C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)O1 QOWAMIUFBNBINS-UHFFFAOYSA-N 0.000 description 1
- OZCYPGKPOUZZSO-UHFFFAOYSA-N 2-chloro-4-iodophenol Chemical compound OC1=CC=C(I)C=C1Cl OZCYPGKPOUZZSO-UHFFFAOYSA-N 0.000 description 1
- OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- DHGPLNJITGVCSG-UHFFFAOYSA-N 4-bromo-2-chlorobenzaldehyde Chemical compound ClC1=CC(Br)=CC=C1C=O DHGPLNJITGVCSG-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 229940048299 ACETYLATED LANOLIN ALCOHOLS Drugs 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N Acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000182185 Alfalfa virus S Species 0.000 description 1
- 229960000458 Allantoin Drugs 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N Dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010058805 Encephalitic infection Diseases 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 102100012247 GRIN2A Human genes 0.000 description 1
- 102100012245 GRIN2B Human genes 0.000 description 1
- 102100012244 GRIN2C Human genes 0.000 description 1
- 102100012243 GRIN2D Human genes 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000033149 HERVK Human genes 0.000 description 1
- 102000015084 HIV Reverse Transcriptase Human genes 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940093629 ISOPROPYL ISOSTEARATE Drugs 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical group NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- UJPPXNXOEVDSRW-UHFFFAOYSA-N Isopropyl_laurate Chemical compound CCCCCCCCCCCC(=O)OC(C)C UJPPXNXOEVDSRW-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 229960001627 Lamivudine Drugs 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 229940078812 MYRISTYL MYRISTATE Drugs 0.000 description 1
- 229940078555 MYRISTYL PROPIONATE Drugs 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 210000004251 Milk, Human Anatomy 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 1
- 108091007966 NR2D Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BMQYVXCPAOLZOK-INEUFUBQSA-N Neopterin Chemical compound C1=C([C@@H](O)[C@H](O)CO)N=C2C(=O)NC(N)=NC2=N1 BMQYVXCPAOLZOK-INEUFUBQSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 231100000618 Neurotoxin Toxicity 0.000 description 1
- 108020005497 Nuclear hormone receptors Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptors Human genes 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 229940054534 Ophthalmic Solution Drugs 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000004129 Prosencephalon Anatomy 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- LOUPRKONTZGTKE-LHHVKLHASA-N Quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010058878 Salmonella sepsis Diseases 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N Simethicone Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M Sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 210000000225 Synapses Anatomy 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N Triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 108009000571 Tryptophan metabolism Proteins 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001773 anti-convulsant Effects 0.000 description 1
- 230000002555 anti-neurodegenerative Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 201000001178 bacterial pneumonia Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- OCXGTPDKNBIOTF-UHFFFAOYSA-N dibromo(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 OCXGTPDKNBIOTF-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- STRNXFOUBFLVIN-UHFFFAOYSA-N diethyl but-2-ynedioate Chemical compound CCOC(=O)C#CC(=O)OCC STRNXFOUBFLVIN-UHFFFAOYSA-N 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- KARVSHNNUWMXFO-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane;hydrate Chemical class O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Al]O[Al]=O KARVSHNNUWMXFO-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002996 emotional Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- HQSFGCUUTBCFPF-UHFFFAOYSA-N ethane-1,2-diol;octadecanoic acid Chemical compound OCCO.CCCCCCCCCCCCCCCCCC(O)=O HQSFGCUUTBCFPF-UHFFFAOYSA-N 0.000 description 1
- RDEDWQDJPRDEBZ-UHFFFAOYSA-N ethyl 4-oxo-1H-pyrimidine-6-carboxylate Chemical compound CCOC(=O)C1=CC(O)=NC=N1 RDEDWQDJPRDEBZ-UHFFFAOYSA-N 0.000 description 1
- DSNWMSGZYSQPTE-UHFFFAOYSA-N ethyl 6-chloropyrimidine-4-carboxylate Chemical compound CCOC(=O)C1=CC(Cl)=NC=N1 DSNWMSGZYSQPTE-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 239000004060 excitotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 229910000286 fullers earth Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 108010060555 gag Gene Products Proteins 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 108091007956 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002197 limbic Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004690 mucosal barrier Effects 0.000 description 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003188 neurobehavioral Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000002981 neuropathic Effects 0.000 description 1
- 230000002237 neuroprotectant Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 230000002887 neurotoxic Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000036963 noncompetitive Effects 0.000 description 1
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002530 poly[4-(4-benzoylphenoxy)phenol] polymer Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 200000000025 progressive disease Diseases 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9Z,12Z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-M pyrimidine-4-carboxylate Chemical class [O-]C(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-M 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010038912 retinoid X receptors Proteins 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-M sulfinate Chemical compound [O-]S=O BUUPQKDIAURBJP-UHFFFAOYSA-M 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 108091007968 testicular receptors Proteins 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000000605 viral structures Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Abstract
Certain adjunctive therapies comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent for treating HIV-related disorders are provided herein. These disorders include AIDS dementia complex, AIDS-induced encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis. Also provided are pharmaceutical compositions comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent.
Description
[001] This application claims the benefit of U.S. Provisional Appln. No. 62/025,840, filed July 17, 2014, which is incorporated herein by reference for all purposes.
[002] Provided herein are certain adjunctive thérapies for HIV-related disorders comprising administering a kynurenine-3-monooxygenase inhibitor with an antiviral agent. Also provided herein are pharmaceutical compositions comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent.
[003] Inflammatory processes contribute significantly to the progression and manifestations of a broad spectrum of central nervous system (CNS) diseases, including acute and chronic microbial infections, autoimmune processes, stroke, and physical trauma to the CNS. There are many mechanisms by which inflammation could cause neurological disease, including the production of neurotoxic agents by the host or invading microbes. Identification of such mediators and the processes that lead to their production and accumulation are important steps in developing rational approaches to therapy. Motor abnormalities, cognitive déficits, and dementia (encephalopathy) are frequent complications of infection with the human immunodeficiency virus (HIV) and can occur independently of opportunistic CNS infections. The most frequent neuropathologic substrate associated with neurological symptoms is HIV encephalitis, an inflammatory condition characterized by the presence of HIV-infected macrophages, astrogliosis, white matter pallor, and neuronal injury (loss of neurons and synapses). The production of toxins by microglia/macrophages has been hypothesized as a possible mechanism responsible for neurological dysfunction and neurodegeneration, because HIV is localized predominantly in microglia/macrophages and because macrophage-tropic isolâtes are associated with neurological disease to a greater extent than T cell tropic isolâtes. Potential host-coded neurotoxins include the NMDA receptor agonist quinolinic acid (QUIN). [004] QUIN is an excitotoxic métabolite ofthe tryptophan-kynurenine pathway. In models of inflammatory neurological disorders such as experimental allergie encephalitis, bacterial and viral infections, forebrain global ischemia or spinal trauma, brain QUIN levels are extremely elevated. This increased brain QUIN concentration could be due to either an elevated circulating concentration ofthe excitotoxin orto an increased de novo synthesis in activated microglia or in infiltrating macrophages. QUIN is an agonist of a subgroup of NMDA receptors and when directly injected into brain areas it destroys most neuronal cell bodies sparing fibers en passant and neuronal terminais. QUIN is a relatively poor agonist ofthe NMDA receptor complex containing either NR2C or NR2D subunits, while it interacts with higher affînity with the NR2A subunit (7-10 pmol) and the NR2B subunit (100 pmol). In vitro, the neurotoxic effects ofthe compound hâve been studied in different model Systems with variable results: chronic exposure of organotypic cortico-striatal cultures to submicromolar concentration of QUIN causes histological signs of pathology; similar results hâve been obtained after chronic exposure of cultured neuronal cells.
[005] Sustained increases in the concentrations of QUIN occur in cérébral spinal fluid (CSF) and blood of HIV-infected patients and macaques infected with the simian immunodeficiency virus (SIV), and begin soon after primary infection. Elevated CSF QUIN is associated with motor déficits and virus recovery from the CNS in the early asymptomatic stages of disease, and correlate with quantitative measures of neuropsychologic déficits, striatal and limbic atrophy, and markers of intrathecal immune activation (CSF p2-microglobulin and neopterin concentrations) in late stage patients. One study reported that in HIV-infected patients, brain QUIN concentrations were elevated by > 300-fold, to concentrations that exceeded cerebrospinal fluid (CSF) by 8.9-fold. Furthermore, in retrovirus-infected macaques, the largest kynurenine pathway responses in brain and CSF were associated with retrovirus-induced encephalitis. Direct measures ofthe amount of QUIN in brain derived from blood in a macaque with encephalitis showed that almost ail QUIN (98%) was synthesized locally within the brain. In contrast to the brain changes, there was no différence in any systemic measure between macaques with encephalitis and those without. These results demonstrate a rôle for induction of indoleamine-2,3-dioxygenase (IDO) in accelerating the local formation of QUIN within the brain tissue, particularly in areas of encephalitis, rather than entry of QUIN into the brain from the méningés or blood. In fact, robust increases in the activities of IDO, and two other enzymes in the kynurenine pathway of tryptophan metabolism, kynurenine-3-monooxygenase (KMO) and kynureninase (KYNU) hâve been found in areas of brain inflammation. Accordingly, strategies to reduce QUIN production, targeted at intracérébral sites, are potential approaches to therapy. [006] The pathogenesis of human and simian immunodeficiency viruses is characterized by CD4(+) T cell déplétion and chronic T cell activation, leading ultimately to AIDS. CD4(+) T helper (T(H)) cells provide protective immunity and immune régulation through different immune cell functional subsets, including T(H)1, T(H)2, T regulatory (T(reg)), and interleukin-17 (IL-17)secreting T(H)17 cells. Because IL-17 can enhance host defenses against microbial agents, thus maintaining the integrity of the mucosal barrier, loss of T(H)17 cells may foster microbial translocation and sustained inflammation. It has been found that in HIV-seropositive subjects progressive disease is associated with the loss of T(H)17 cells and a reciprocal increase in the fraction ofthe immunosuppressive T(reg) cells both in peripheral blood and in rectosigmoid biopsies. The loss of T(H)17/T(reg) balance is associated with induction of indoleamine-2,3dioxygenase 1 (IDO1) by myeloid antigen-presenting dendritic cells and with increased plasma concentration of microbial products. In vitro, the loss of T(H)17/T(reg) balance is mediated directly by the proximal tryptophan catabolite from IDO metabolism, 3-hydroxyanthranilic acid (3-OH-AA). It has been postulated that induction of IDO may represent a critical initiating event that results in inversion of the T(H)17/T(reg) balance and in the conséquent maintenance of a chronic inflammatory state in progressive HIV disease. Accordingly, strategies to lower 3-OHAA levels are predicted to eliminate orameliorate systemic inflammation after HIV infection. [007] KMO catalyzes the conversion of kynurenine (KYN) into 3-hydroxykynurenine (3-HK or 3-OH-KYN), which is further degraded by KYNU to 3-hydroxyanthranilic acid, and then to QUIN. 3-OH-KYN and QUIN act synergistically, i.e. 3-OH-KYN significantly potentiates the excitotoxic actions of QUIN. Studies from several laboratories hâve provided evidence that the shift of KYN pathway metabolism away from the 3-OH-KYN/QUIN branch to increase the formation of the neuroprotectant KYNA (kynurenic acid) in the brain leads to neuroprotection.
[008] In addition to having effects in the brain, the inhibition of KMO is further contemplated to impact peripheral tissues. Based on the rôle of 3-OH-AA in the modulation of T(H)17 cells and IL-17/IL-23 balance in HIV pathogenesis, KMO inhibitors are predicted to prevent increase in microbial translocation across the gastrointestinal mucosa and systemic inflammation in longterm progressors. Thus, the inhibition of KMO may be useful in the treatment of peripheral HIVrelated disorders as well as diseases of the brain.
[009] Compounds and pharmaceutically acceptable salts thereof described herein that inhibit KMO are disclosed in PCT patent publications WO2013/033068 and WO2013/033085, each of which is incorporated herein by reference in its entirety.
[010] There remains a need for methods and compositions that are effective in adjunctively treating disorders associated with HIV infection.
[011] Accordingly, provided is a method of treating an HIV-related disorder in a subject infected with HIV, comprising adjunctively administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
R2
Formula I or a pharmaceutically acceptable sait thereof;
wherein the subject is also being administered an antiviral agent; and further wherein:
R1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C-iC4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo.
[012] Also provided is a composition comprising an antiviral agent and a compound of Formula I:
Formula I or a pharmaceutically acceptable sait thereof;
wherein:
R1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C1C4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo.
BRIEF DESCRIPTION OF THE DRAWINGS [013] FIG 1. shows the dose dépendent increase of kynurenine (KYN) in the striatum extracellular space following dosing of Compound 6.
[014] FIG 2. shows the dose dépendent increase of kynurenic acid (KYNA) in the striatum extracellular space following dosing of Compound 6.
[015] FIG 3. shows the dose dépendent increase of anthranilic acid (AA) in the striatum extracellular space following dosing of Compound 6.
[016] FIG 4. shows insufficient modulation of 3-hydroxykynurenine (3-HKor3-OH-KYN) in the striatum extracellular space following dosing of Compound 6.
[017] FIG 5. shows the dose dépendent increase of kynurenine pathway (KP) métabolites in the striatum following dosing of Compound 6 in wild type mice.
[018] FIG 6. shows the dose dépendent increase of kynurenine pathway métabolites in the striatum following dosing of Compound 6 in Q175_KI homozygous mice.
[019] FIG 7. shows the modulation of KYN in the striatum following dosing of Compound 6, KYN, and (Compound 6 + KYN).
[020] FIG 8. shows the modulation of KYNA in the striatum following dosing of Compound 6, KYN, and (Compound 6 + KYN).
[021] FIG 9. shows the modulation of anthranilic acid (AA) in the striatum following dosing of Compound 6, KYN, and (Compound 6 + KYN).
[022] FIG 10. shows the modulation of 3-OH-KYN in the striatum following dosing of Compound 6, KYN, and (Compound 6 + KYN).
[023] FIG 11. shows the modulation of quinolinic acid (QA) in the striatum following dosing of Compound 6, KYN, and (Compound 6 + KYN).
[024] As used in the présent spécification, the following words, phrases and symbols are generally intended to hâve the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. The following abbreviations and terms hâve the indicated meanings throughout:
[025] A dash (“—”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —CONH2 is attached through the carbon atom. [026] The term “alkoxy” refers to an alkyl group of the indicated number of carbon atoms attached through an oxygen bridge such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, terf-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, and the like. By “cycloalkoxy” is meant a cycloalkyl group, as defined herein, that is likewise attached through an oxygen bridge.
[027] The term “alkyl” encompasses straight chain and branched chain having the indicated number of carbon atoms, usually from 1 to 20 carbon atoms, for example 1 to 8 carbon atoms, such as 1 to 6 carbon atoms. For example C1-C6 alkyl encompasses both straight and branched chain alkyl of from 1 to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and the like. When an alkyl residue having a spécifie number of carbons is named, ail géométrie isomers having that number of carbons are intended to be encompassed; thus, for example, “butyl” is meant to include n-butyl, sec-butyl, isobutyl and tertbutyl; “propyl” includes n-propyl and isopropyl.
[028] The term “cycloalkyl” refers to a saturated hydrocarbon ring group, having the specified number of carbon atoms,, usually from 3 to 7 ring carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl as well as bridged and caged saturated ring groups such as norbomane.
[029] The term “halo” refers to fluoro, chloro, bromo, and iodo.
[030] By “optional” or “optionally” is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” encompasses both “alkyl” and “substituted alkyl” as defined below. Itwill be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible and/or inherently unstable. [031] The term “substituted”, as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a sélection from the indicated group, provided that the designated atom’s normal valence is not exceeded. When a substituent is oxo (i.e., =O) then 2 hydrogens on the atom are replaced. Combinations of substituents and/or variables are permissible only if such combinations resuit in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subséquent formulation as an agent having at least practical utility. Unless otherwise specified, substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent, the point of attachment of this substituent to the core structure is in the alkyl portion.
[032] Compounds described herein include, but are not limited to, their optical isomers, racemates, and other mixtures thereof. In those situations, the single enantiomers or diastereomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution ofthe racemates. Resolution ofthe racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high- pressure liquid chromatography (HPLC) column. The term “isomers” refers to different compounds that hâve the same molecular formula. The term “stereoisomers” refers to isomers that differ only in the way the atoms are arranged in space. The term “enantiomers” refers to stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The symbol “(+)” may be used to designate a racemic mixture where appropriate. The term “diastereoisomers” refers to stereoisomers that hâve at least two asymmetric atoms, but which are not mirror-images of each other. The term “meso compound” or “meso isomer” refers to a non-optically active member of a set of stereoisomers. Meso isomers contain two or more stereocenters but are not chiral (i.e., a plane of symmetry exists within the molécule). The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized lightatthewavelength ofthe sodium D line.
[033] Where compounds described herein exist in various tautomeric forms, the term “compound” includes ail tautomeric forms ofthe compound. Such compounds also include crystal forms including polymorphs and clathrates. Similarly, the term “sait” includes ail tautomericforms and crystal forms ofthe compound. The term “tautomers” refers to structurally distinct isomers that interconvert by tautomerization. Tautomerization is a form of isomerization and includes prototropic or proton-shift tautomerization, which is considered a subset of acidbase chemistry. Prototropic tautomerization or proton-shift tautomerization involves the migration of a proton accompanied by changes in bond order, often the interchange of a single bond with an adjacent double bond. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached. An example of tautomerization is keto-enol tautomerization. A spécifie example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A spécifie example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1H)“°ne tautomers.
[034] Pharmaceutically acceptable forms ofthe compounds recited herein include pharmaceutically acceptable salts, prodrugs, and mixtures thereof. In some embodiments, the compounds described herein are in the form of pharmaceutically acceptable salts and prodrugs. [035] “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stéarate, and alkanoate such as acetate, HOOC-(CH2)n-COOH where n is 0-4, and like salts. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium. In addition, if the compounds described herein are obtained as an acid addition sait, the free base can be obtained by basifÿing a solution ofthe acid sait. Conversely, if the product is a free base, an addition sait, particularly a pharmaceutically acceptable addition sait, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic méthodologies that may be used to préparé non-toxic pharmaceutically acceptable addition salts.
[036] The term “prodrug” refers to a substance administered in an inactive or less active form that is then transformed (e.g., by metabolic processing of the prodrug in the body) into an active compound. The rationale behind administering a prodrug is to optimize absorption, distribution, metabolism, and/or excrétion of the drug. Prodrugs may be obtained by making a dérivative of an active compound (e.g., a compound of Formula I or another compound disclosed and/or described herein) that will undergo a transformation under the conditions of use (e.g., within the body) to form the active compound. The transformation of the prodrug to the active compound may proceed spontaneously (e.g., by way of a hydrolysis reaction) or it can be catalyzed or induced by another agent (e.g., an enzyme, light, acid or base, and/or température). The agent may be endogenous to the conditions of use (e.g., an enzyme présent in the cells to which the prodrug is administered, or the acidic conditions of the stomach) or the agent may be supplied exogenously. Prodrugs can be obtained by converting one or more functional groups in the active compound into another functional group, which is then converted back to the original functional group when administered to the body. For example, a hydroxyl functional group can be converted to a sulfonate, phosphate, ester or carbonate group, which in turn can be hydrolyzed in vivo back to the hydroxyl group. Similarly, an amino functional group can be converted, for example, into an amide, carbamate, imine, urea, phosphenyl, phosphoryl or sulfenyl functional group, which can be hydrolyzed in vivo back to the amino group. A carboxyl functional group can be converted, for example, into an ester (including silyl esters and thioesters), amide or hydrazide functional group, which can be hydrolyzed in vivo back to the carboxyl group. Examples of prodrugs include, but are not limited to, phosphate, acetate, formate and benzoate dérivatives of functional groups (such as alcohol or amine groups) présent in the compounds of Formula I and other compounds disclosed and/or described herein. In some embodiments, the “prodrugs” described herein include any compound that becomes a compound of Formula I when administered to a patient, e.g., upon metabolic processing ofthe prodrug. Examples of prodrugs include dérivatives of functional groups, such as a carboxylic acid group, in the compounds of Formula I. Exemplary prodrugs of a carboxylic acid group include, but are not limited to, carboxylic acid esters such as alkyl esters, hydroxyalkyl esters, arylalkyl esters, and aryloxyalkyl esters. Other exemplary prodrugs include lower alkyl esters such as ethyl ester, acyloxyalkyl esters such as pivaloyloxymethyl (POM), glycosides, and ascorbic acid dérivatives. Other exemplary prodrugs include amides of carboxylic acids. Exemplary amide prodrugs include metabolically labile amides that are formed, for example, with an amine and a carboxylic acid. Exemplary amines include NH2, primary, and secondary amines such as NHRX, and NRxRy, wherein Rx is hydrogen, (C-i-C-ie)-alkyl, (C3-C7) cycloalkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkyl—, (C6-Ci4)-aryl which is unsubstituted or substituted by a residue (Ci-C2)-alkyl, (Ci-C2)-alkoxy, fluoro, or chloro; heteroaryl, (C6- C-i4)-aryl-(C-i-C4)alkyl—where aryl is unsubstituted or substituted by a residue (Ci-C2)-alkyl, (Ci-C2)-alkoxy, fluoro, or chloro; or heteroaryl-(Ci-C4)-alkyl— and in which Ry has the meanings indicated for Rx with the exception of hydrogen or wherein Rx and Ry, together with the nitrogen to which they are bound, form an optionally substituted 4- to 7- membered heterocycloalkyl ring which optionally includes one or two additional heteroatoms chosen from nitrogen, oxygen, and sulfur. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 ofthe A.C.S. Symposium Sériés, in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
[037] The compounds described herein can be enriched isotopic forms, e.g., enriched in the content of 2H, 3H, 11C, 13C and/or 14C. In one embodiment, the compound contains at least one deuterium atom. Such deuterated forms can be made, for example, by the procedure described in U.S. Patent Nos. 5,846,514 and 6,334,997. Such deuterated compounds may improve the efficacy and increase the duration of action of compounds disclosed and/or described herein. Deuterium substituted compounds can be synthesized using various methods, such as those described in: Dean, D., Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development, Curr. Pharm. Des., 2000; 6(10); Kabalka, G. et al., The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E., Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981,64(1-2), 9-32.
[038] A “solvaté” refers to an entity formed by the interaction of a solvent and a compound or a pharmaceutically acceptable sait thereof. The term “compound” is intended to include solvatés of compounds. Similarly, “salts” includes solvatés of salts. Suitable solvatés are pharmaceutically acceptable solvatés, such as hydrates, including monohydrates and hemihyd rates.
[039] A “chelate” refers to an entity formed by the coordination of a compound to a métal ion at two (or more) points. The term “compound” is intended to include chelates of compounds. Similarly, “salts” includes chelates of salts.
[040] A “non-covalent complex” refers to an entity formed by the interaction of a compound and another molécule wherein a covalent bond is not formed between the compound and the molécule. For example, complexation can occur through van derWaals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding). Such non-covalent complexes are included in the term “compound”.
[041] The term “hydrogen bond” refers to a form of association between an electronegative atom (also known as a hydrogen bond acceptor) and a hydrogen atom attached to a second, relatively electronegative atom (also known as a hydrogen bond donor). Suitable hydrogen bond donor and acceptors are well understood in médicinal chemistry (G. C. Pimentel and A. L. McClellan, The Hydrogen Bond, Freeman, San Francisco, 1960; R. Taylor and O. Kennard, “Hydrogen Bond Geometry in Organic Crystals”, Accounts of Chemical Research, 17, pp. 320326 (1984)).
[042] “Hydrogen bond acceptor” refers to a group comprising an oxygen or nitrogen, such as an oxygen or nitrogen that is sp2-hybridized, an ether oxygen, or the oxygen of a sulfoxide or N-oxide.
[043] The term “hydrogen bond donor” refers to an oxygen, nitrogen, or heteroaromatic carbon that bears a hydrogen group containing a ring nitrogen or a heteroaryl group containing a ring nitrogen.
[044] As used herein the terms “group”, “radical” or “fragment” refer to a functional group or fragment of a molécule attachable to a bond or other fragments of molécules.
[045] The term “active agent” refers to a compound or a pharmaceutically acceptable sait thereof which has biological activity. In some embodiments, an “active agent” is a compound or a pharmaceutically acceptable sait thereof having pharmaceutical utility. For example an active agent may be an anti-neurodegenerative therapeutic or an antiviral therapeutic.
[046] The term “therapeutically effective amount” of a compound, or a pharmaceutically acceptable sait thereof, described herein, refers to an amount effective, when administered to a human or non-human subject, to provide a therapeutic benefit such as amelioration of symptoms, slowing of disease progression, or prévention of disease e.g., a therapeutically effective amount may be an amount sufficient to decrease the symptoms of a disease responsive to inhibition of KMO activity and modulation of kynurenine pathway métabolites (such as kynurenine, kynurenic acid, anthranilic acid, 3-OH-kynurenine, 3-OH anthranilic acid, or quinolinic acid). In some embodiments, a therapeutically effective amount is an amount sufficient to treat the symptoms of an HIV-related disorder. In some embodiments a therapeutically effective amount is an amount sufficient to reduce the signs or side effects of an HIV-related disorder. In some embodiments, a therapeutically effective amount of a compound or a pharmaceutically acceptable sait thereof is an amount sufficient to prevent a significant increase or significantly reduce the level of HIV-related neuronal cell death. In some embodiments, a therapeutically effective amount of a compound or a pharmaceutically acceptable sait thereof is an amount sufficient to prevent a significant increase or significantly reduce the level of QUIN associated with HIV-related neuronal cell death. In some embodiments, a therapeutically effective amount is an amount sufficient to effect an increase in the level of KYNA associated with neuronal cell health in an HIV-infected patient. In some embodiments, a therapeutically effective amount is an amount sufficient to increase the anticonvulsant and neuroprotective properties associated with lowered levels of QUIN and increased levels of KYNA in an HIV-infected patient. In some embodiments, a therapeutically effective amount is an amount sufficient to modulate an inflammatory process in an HIV-infected patient, including but not limited to inflammation in the brain, spinal cord, and peripheral nervous system, or méningés. In methods described herein for adjunctively treating an HIV-related disorder, a therapeutically effective amount may also be an amount sufficient, when administered to a patient, to detectably slowthe progression ofthe HIV-related disorder, or preventthe patienttowhom the composition is given from presenting symptoms ofthe HIVrelated disorder. In some methods described herein for treating an HIV-related disorder, a therapeutically effective amount may also be an amount sufficient to produce a détectable decrease in the level of HIV-related neuronal cell death. For example, in some embodiments a therapeutically effective amount is an amount sufficient to significantly decrease the level of HIV-related neuronal death by effecting a détectable decrease in the amount of QUIN, and an increase in the amount of kynurenine, KYNA, oranthranilic acid. In addition, an amount is considered to be a therapeutically effective amount if it is characterized as such by at least one of the above criteria or experimental conditions, regardless of any inconsistent or contradictory results under a different set of criteria or experimental conditions.
[047] The term “inhibition” indicates a significant decrease in the baseline activity of a biological activity or process. “Inhibition of KMO activity” refers to a decrease in KMO activity as a direct or indirect response to the presence of at least one compound or a pharmaceutically acceptable sait thereof described herein, relative to the activity of KMO in the absence of at least one compound or a pharmaceutically acceptable sait thereof. The decrease in activity may be due to the direct interaction of the compound or a pharmaceutically acceptable sait thereof with KMO, or due to the interaction ofthe compound or a pharmaceutically acceptable sait thereof described herein with one or more other factors that in turn affect KMO activity. For example, the presence ofthe compound or a pharmaceutically acceptable sait thereof may decrease KMO activity by directly binding to the KMO, by causing (directly or indirectly) another factor to decrease KMO activity, or by (directly or indirectly) decreasing the amount of KMO présent in the cell or organism. Inhibition of KMO activity also refers to an observable inhibition of 3-HK and QUIN production in a standard assay such as the assays described below. The inhibition of KMO activity also refers to an observable increase in the production of KYNA. In some embodiments, the compound or a pharmaceutically acceptable sait thereof described herein has an IC50 value less than orequal to 1 micromolar. In some embodiments, the compound or a pharmaceutically acceptable sait thereof has an IC50 value less than or equal to less than 100 micromolar. In some embodiments, the compound or a pharmaceutically acceptable sait thereof has an IC50 value less than or equal to 10 nanomolar. Inhibition of KMO activity also refers to activation, redistribution, reorganization, or capping of one or more various KMO membrane-associated proteins (such as those receptors found in the mitochondria), or binding sites can undergo redistribution and capping that can initiate signal transduction. KMO activity also can modulate the availability of kynurenine, which can effect the synthesis or production of QUIN, KYNA, anthranilic acid, and/or 3-HK.
[048] A “disease responsive to inhibition of KMO activity” refers to a disease in which inhibiting KMO provides a therapeutic benefit such as an amelioration of symptoms, decrease in disease progression, prévention ordelay of disease onset, prévention or amelioration of an inflammatory response, or inhibition of aberrant activity and/or death of certain cell-types (such as neuronal cells).
[049] “Treatment” or “treating” refers to any treatment of a disease in a patient, including: a) preventing the disease, that is, causing the clinical symptoms ofthe disease not to develop; b) inhibiting the progression ofthe disease; c) slowing orarresting the development of clinical symptoms; and/or d) relieving the disease, that is, causing the régression of clinical symptoms. [050] “Subject” or “patient1 refers to an animal, such as a mammal, that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in both human therapy and veterinary applications. In some embodiments, the subject is a mammal; and in some embodiments the subject is human.
[051] The term “disease” refers to an abnormal condition of the human or animal body or of one or more of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to hâve a reduced duration or quality of life. As used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder” and “condition” (as in medical condition).
[052] The term “adjunctively” refers to the administering to a patient, or treating a patient with, at least one compound, or a pharmaceutically acceptable sait thereof, described herein, in addition to an antiviral agent, either simultaneously, orat intervals prior to, during, or following administration of the antiviral agent to achieve the desired therapeutic effect.
[053] The term “viral load” refers to the concentration of a virus, such as HIV, in the blood. [054] Provided is a composition comprising an antiviral agent and a compound of Formula I:
R2
Formula I or a pharmaceutically acceptable sait thereof;
wherein:
R1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C-iC4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo.
[055] In some embodiments, R1 is C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent.
[056] In some embodiments, R1 is C1-C4 alkoxy.
[057] In some embodiments, R1 is sec-butoxy.
[058] In some embodiments, R1 is (R)-sec-butoxy.
[059] In some embodiments, R1 is (S)-sec-butoxy.
[060] In some embodiments, R1 is isopropoxy.
[061] In some embodiments, R1 is C1-C4 alkoxy substituted with one C3-C6 cycloalkyl substituent.
[062] In some embodiments, R1 is cyclopropylmethoxy.
[063] In some embodiments, R1 is C1-C4 alkyl substituted with one substituent selected from C1-C4 alkoxy and C3-C6 cycloalkoxy.
[064] In some embodiments, R1 is C1-C4 alkyl substituted with one C1-C4 alkoxy substituent. [065] In some embodiments, R1 is 1-methoxyethyl.
[066] In some embodiments, R1 is methoxymethyl.
[067] In some embodiments, R1 is C-1-C4 alkyl substituted with one C3-C6 cycloalkoxy substituent.
[068] In some embodiments, R1 is 1-cyclopropoxyethyl.
[069] In some embodiments, R1 is cyclopropoxymethyl.
[070] In some embodiments, R1 is C3-C6 cycloalkoxy.
[071] In some embodiments, R1 is cyclobutoxy.
[072] In some embodiments, R1 is cyclopentyloxy.
[073] In some embodiments, R1 is cyclopropoxy.
[074] In some embodiments, R1 is halo.
[075] In some embodiments, R1 is chloro.
[076] In some embodiments, R1 is fluoro.
[077] In some embodiments, R2 is selected from: C1-C4 alkoxy, C3-C6 cycloalkoxy, and halo.
[078] In some embodiments, R2 is C1-C4 alkoxy.
[079] In some embodiments, R2 is isobutoxy.
[080] In some embodiments, R2 is isopropoxy.
[081] In some embodiments, R2 is methoxy.
[082] In some embodiments, R2 is C3-C6 cycloalkoxy.
[083] In some embodiments, R2 is cyclopropoxy.
[084] In some embodiments, R2 is halo.
[085] In some embodiments, R2 is chloro.
[086] In some embodiments, R2 is fluoro.
[087] In some embodiments, R1 is selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C-1-C4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo; and R2 is selected from: C1-C4 alkoxy, C3-C6 cycloalkoxy, and halo.
[088] In some embodiments, R1 is selected from sec-butoxy, chloro, cyclobutoxy, cyclopentyloxy, cyclopropoxy, 1-cyclopropoxyethyl, cyclopropylmethoxy, cyclopropoxymethyl, fluoro, methoxy, 1-methoxyethyl, and methoxymethyl; and R2 is selected from: chloro, cyclopropoxy, fluoro, isobutoxy, isopropoxy, and methoxy.
[089] In some embodiments, the compound of Formula I is selected from: 6-(4-chloro-3-methoxyphenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-isopropoxyphenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-(cyclopentyloxy)phenyl)pyrimidine-4-carboxylic acid; (S)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid; (R)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-cyclobutoxyphenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-(cyclopropylmethoxy)phenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-(methoxymethyl)phenyl)pyrimidine-4-carboxylic acid;
6-(3-chloro-4-(1-methoxyethyl)phenyl)pyrimidine-4-carboxylic acid;
6-(3-chloro-4-(cyclopropoxymethyl)phenyl)pyrimidine-4-carboxylic acid;
6-(3-chloro-4-(1-cyclopropoxyethyl)phenyl)pyrimidine-4-carboxylic acid;
6-(4-chloro-3-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid;
6-(4-chloro-3-isopropoxyphenyl)pyrimidine-4-carboxylic acid;
6-(4-chloro-3-fluorophenyl)pyrimidine-4-carboxylic acid;
6-(3-chloro-4-fluorophenyl)pyrimidine-4-carboxylic acid;
6-(3,4-dichlorophenyl)pyrimidine-4-carboxylic acid;
6-(3,4-difluorophenyl)pyrimidine-4-carboxylic acid; and
6-(3-chloro-4-methoxy)pyrimidine-4-carboxylic acid.
[090] In some embodiments, the compound of Formula I is 6-(4-chloro-3methoxyphenyl)pyrimidine-4-carboxylic acid.
[091] In some embodiments, the compound of Formula I is 6-(3-chloro-4isopropoxyphenyl)pyrimidine-4-carboxylic acid.
[092] In some embodiments, the compound of Formula I is 6-(3-chloro-4(cyclopentyloxy)phenyl)pyrimidine-4-carboxylic acid.
[093] In some embodiments, the compound of Formula I is (S)-6-(4-sec-butoxy-3chlorophenyl)pyrimidine-4-carboxylic acid.
[094] In some embodiments, the compound of Formula I is (R)-6-(4-sec-butoxy-3chlorophenyl)pyrimidine-4-carboxylic acid.
[095] In some embodiments, the compound of Formula I is 6-(3-chloro-4cyclopropoxyphenyl)pyrimidine-4-carboxylic acid.
[096] In some embodiments, the compound of Formula I is 6-(3-chloro-4cyclobutoxyphenyl)pyrimidine-4-carboxylic acid.
[097] In some embodiments, the compound of Formula I is 6-(3-chloro-4(cyclopropylmethoxy)phenyl)pyrimidine-4-carboxylic acid.
[098] In some embodiments, the compound of Formula I is 6-(3-chloro-4(methoxymethyl)phenyl)pyrimidine-4-carboxylic acid.
[099] In some embodiments, the compound of Formula I is 6-(3-chloro-4-(1methoxyethyl)phenyl)pyrimidine-4-carboxylic acid.
[0100] In some embodiments, the compound of Formula I is 6-(3-chloro-4(cyclopropoxymethyl)phenyl)pyrimidine-4-carboxylic acid.
[0101] In some embodiments, the compound of Formula I is 6-(3-chloro-4-(1cyclopropoxyethyl)phenyl)pyrimidine-4-carboxylic acid.
[0102] In some embodiments, the compound of Formula I is 6-(4-chloro-3cyclopropoxyphenyl)pyrimidine-4-carboxylic acid.
[0103] In some embodiments, the compound of Formula I is 6-(4-chloro-3isopropoxyphenyl)pyrimidine-4-carboxylic acid.
[0104] In some embodiments, the compound of Formula i is 6-(4-chloro-3fluorophenyl)pyrimidine-4-carboxylic acid.
[0105] In some embodiments, the compound of Formula I is 6-(3-chloro-4fluorophenyl)pyrimidine-4-carboxylic acid.
[0106] In some embodiments, the compound of Formula I is 6-(3,4-dichlorophenyl)pyrimidine-4carboxylic acid.
[0107] In some embodiments, the compound of Formula I is 6-(3,4-difluorophenyl)pyrimidine-4carboxylic acid.
[0108] In some embodiments, the compound of Formula I is 6-(3-chloro-4-methoxy)pyrimidine4-carboxylic acid.
[0109] Also provided is a composition comprising an antivirai agent and a compound selected from the compounds shown in Table A below, or a pharmaceutically acceptable sait thereof.
Table A
Compound No. | Chemical Structure | Chemical Name |
1 | N^N ci^y ° /O | 6-(4-chloro-3-methoxy- phenyl)pyrimidine-4-carboxylic acid |
2 | N^N Cl | 6-(3-chloro-4-isopropoxy- phenyl)pyrimidine-4-carboxylic acid |
3 | ΝΆ AojÇAï Cl | 6-(3-chloro-4-(cyclopentyloxy)- phenyl)pyrimidine-4-carboxylic acid |
Compound No. | Chemical Structure | Chemical Name |
4 | N^N Cl | (S)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid |
5 | N^N u-ov^i Cl | (R)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid |
6 | N^N AAf* ° Cl | 6-(3-chloro-4-cyclopropoxy- phenyl)pyrimidine-4-carboxylic acid |
7 | ΝΆ aol/ï Cl | 6-(3-chloro-4-cyclobutoxy- phenyl)pyrimidine-4-carboxylic acid |
8 | N^N z^JUk/OH V Cl | 6-(3-chloro-4-(cyclopropylmethoxy)- phenyl)pyrimidine-4-carboxyiic acid |
9 | N^N 0 Cl | 6-(3-chloro-4-(methoxymethyl)- phenyl)pyrimidine-4-carboxylic acid |
10 | N^N /^AA/h 0 I Cl | 6-(3-chloro-4-(1-methoxyethyl)- phenyl)pyrimidine-4-carboxylic acid |
11 | N^N ^ΑΑ+Ααπ _/O^LJ 0 | 6-(3-chloro-4-(cyclopropoxymethyl)- phenyl)pyrimidine-4-carboxylic acid |
Compound No. | Chemical Structure | Chemical Name |
12 | ΝΎ __0 % TT | 6-(3-chloro-4-(1-cyclopropoxyethyl)- phenyl)pyrimidine-4-carboxylic acid |
13 | N^N CI-Y 0 Y | 6-(4-chloro-3-cyclopropoxy- phenyl)pyrimidine-4-carboxylic acid |
14 | N^Y c,YS Y | 6-(4-chloro-3-isopropoxy- phenyl)pyrimidine-4-carboxylic acid |
15 | ΝΎ x“ | 6-(4-chloro-3-isobutoxy- phenyl)pyrimidine-4-carboxylic acid |
16 | N^N YY^^\r0H CI-V F | 6-(4-chloro-3-fluoro- phenyl)pyrimidine-4-carboxylic acid |
17 | N^N Cl | 6-(3-chloro-4-fluoro- phenyl)pyrimidine-4-carboxylic acid |
18 | N^N z+X+Jk/OH αγγ Cl | 6-(3,4-dichloro-phenyl)pyrimidine-4carboxylic acid |
Compound No. | Chemical Structure | Chemical Name |
19 | N^N F | 6-(3,4-difluoro-phenyl)pyrimidine-4carboxylic acid |
20 | N^N Cl | 6-(3-chloro-4-methoxy)pyrimidine-4carboxylic acid |
[0110] Methods forobtaining the compounds, or pharmaceutically acceptable salts thereof, described herein will be apparent to those of ordinary skill in the art, suitable procedures being described, for example, in examples below, and in the référencés cited herein.
[0111] Provided is a method of treating a disorder in a subject infected with HIV, comprising adjunctively administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
Formula I or a pharmaceutically acceptable sait thereof;
wherein the subject is also being administered an antiviral agent; and further wherein:
R1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C-iC4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo.
[0112] Provided is a method of lowering HIV viral load in a subject infected with HIV, comprising adjunctively administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
Compound No. | Chemical Structure | Chemical Name |
19 | N^N F | 6-(3,4-difluoro-phenyl)pyrimidine-4carboxylic acid |
20 | N^N Cl | 6-(3-chloro-4-methoxy)pyrimidine-4carboxylic acid |
[0110] Methods forobtaining the compounds, or pharmaceutically acceptable salts thereof, described herein will be apparent to those of ordinary skill in the art, suitable procedures being described, for example, in examples below, and in the référencés cited herein.
[0111] Provided is a method of treating a disorder in a subject infected with HIV, comprising adjunctively administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
Formula I or a pharmaceutically acceptable sait thereof;
wherein the subject is also being administered an antiviral agent; and further wherein:
R1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C-iC4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo.
[0112] Provided is a method of lowering HIV viral load in a subject infected with HIV, comprising adjunctively administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:
Formula I or a pharmaceutically acceptable sait thereof;
wherein the subject is also being administered an antiviral agent; and further wherein:
R1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C1C4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo.
[0113] HIV drugs are classified into six drug classes on the basis of how each drug interfères with the HIV life cycle. These six classes include the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (Pis), fusion inhibitors, CCR5 antagonists, and integrase strand transfer inhibitors (INSTIs). HIV uses reverse transcriptase (RT) to convert its RNA into DNA (reverse transcription). Blocking RT and reverse transcription prevents HIV from replicating. NRTIs lack a 3’ hydroxyl group and are metabolically activated by host cellular kinases to their corresponding 5’-triphosphate forms, which are subsequently incorporated into DNA by HIV reverse transcriptase (RT) and which act as chain terminators of DNA synthesis. Examples of NRTIs include amdoxovir, Combivir®, Emtriva®, Epivir®, Epzicom®, Retrovir®, tenofovir alafenamide fumarate, Trizivir®, Truvada®, Videx®, Videx® EC, Viread®, Zerit®, and Ziagen®. NNRTIs are noncompetitive inhibitors of DNA polymerization, binding to a hydrophobie pocket in RT near the polymerase active site. Examples of NRTIs include Edurant®, Intelence®, lersivirine, Rescriptor®, Sustiva®, Viramune®, and Viramune® XR. After transcription in the nucléus, viral mRNA enters the cytoplasm and uses the host's cellular machinery to manufacture virus proteins. The viral components then gather at the cell membrane and immature viruses bud off the cell. Core proteins are produced as part of long polypeptides, which must be eut into smaller fragments by the enzyme protease in order to form mature, functional proteins. Pis bind to the site where protein cutting occurs, and so prevent the enzyme from releasing the individual core proteins. In this way the new viral particles are unable to mature or become infectious. Examples of Pis include Aptivus®, Crixivan®, Invirase®, Kaletra®, Lexiva®, Norvir®, Prezista®, Reyataz®, and Viracept®. Fusion inhibitors block the HIV envelope from merging with the host cell membrane (fusion), which prevents HIV from entering the host cell. Examples of fusion inhibitors include Fuzeon®. CCR5 antagonists block the CCR5 receptor on the surface of certain immune cells, such as CD4+ cells, which prevents HIV from entering the cell. Examples of CCR5 antagonists include cenicriviroc and Selzentry®. INSTIs block integrase, an enzyme HIV uses to insert (integrate) its viral DNA into the DNA of the host cell. Blocking integrase prevents HIV from replicating. Examples of INSTIs include Isentress®, Tivicay®, and Elvitegravir®. Multi-class combination drugs include Atripla® (efavirenz + tenofovir + emtricitabine), Comptera® (rilpivirine + tenofovir + emtricitabine), Stribild® (elvitegravir + cobicistat + tenofovir + emtricitabine), and Trii™ (dolutegravir + abacavir + lamivudine). Recommended antirétroviral therapy (ART) regimens for the treatment of HIV involve using a combination of three or more antirétroviral (ARV) drugs from at least two different HIV drug classes. The current standard of care for HIV/AIDS in the developed world is highly active antirétroviral therapy (HAART) therapy, usually a combination of two reverse transcriptase inhibitors and a protease inhibitor. Class-sparing regimens purposefully exclude ail ARV drugs from a spécifie drug class to save spécifie ARV drugs for future use in case a regimen needs to be changed because of toxicity or drug résistance. A class-sparing regimen may also be used to avoid adverse effects associated with a spécifie drug class. Certain HIV ART regimens include a pharmacokinetic enhancerthat increases the level of certain ARVs in the blood and make them more effective. Examples of pharmacokinetic enhancers include Cobicistat®, a component of the approved fixed-dose combination tablet Stribild®; ritonavir, a PI that improves the pharmacokinetic (PK) profites of concomitant Pis; and SPI-452. Experimental immune-based HIV thérapies include, Aralen®, DermaVir®, interleukin-7, lexgenleucel-T, Plaquenil®, Proleukin®, and SB-728-T. Entry inhibitors are a class of ARVs that include fusion inhibitors, CCR5 antagonists, and glycosidase inhibitors. Maturation inhibitors are a class of ARVs that target the gag polyprotein precursor, the main structural protein responsible for assembly and budding of virion particles during maturation.
[0114] In some embodiments, the antiviral agent is selected from: entry inhibitors, fusion inhibitors, glycosidase inhibitors, CCR5 antagonists, immune-based thérapies, integrase inhibitors, maturation inhibitors, multi-class combination drugs, non-nucleoside reverse transcriptase inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors, pharmacokinetic enhancers, and protease inhibitors, and combinations thereof.
[0115] In some embodiments, the antiviral agent is selected from: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, CCR5 antagonists, and integrase strand transfer inhibitors, and combinations thereof.
[0116] In some embodiments, the antiviral agent is selected from: amdoxovir, Aptivus®, Aralen®, Atripla®, cenicriviroc, Cobicistat®, Combivir®, Complera®, Crixivan®, DermaVir®, Edurant®, elvitegravir, Emtriva®, Epivir®, Epzicom®, Fuzeon®, ibalizumab, Intelence®, interleukin-7, Invirase®, Isentress®, Kaletra®, lersivirine, lexgenleucel-T, Lexiva®, Norvir®, Plaquenil®, Proleukin®, Prezista®, PRO 140, Rescriptor®, Retrovir®, Reyataz®, SB-728-T, Selzentry®, SPI-452, Stribild®, Sustiva®, tenofovir alafenamide fumarate, Tivicay®, Trii™, Trizivir®, Truvada®, Videx®, Videx® EC, Viracept®, Viramune®, Viramune® XR, Viread®, Zerit®, and Ziagen®, and combinations thereof.
[0117] In some embodiments, the antiviral agent is HAART.
[0118] Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS), which is the most advanced stage of HIV infection. HIV destroys the CD4(+) T lymphocytes (CD4(+) cells) ofthe immune system, leaving the body vulnérable to life-threatening infections and cancers. HIV is a retrovirus that occurs as two types: HIV-1 and HIV-2. Both types are transmitted through direct contact with HIV-infected body fluids, such as blood, semen, and génital sécrétions, or from an HIV-infected motherto her child during pregnancy, birth, or breastfeeding (through breast milk). HIV-1 can be classified into four groups: M Group, N Group, O Group, and P Group. Viruses within each group can then be further classified by subtype. For example, the HIV-1 M group includes at least nine subtypes: A1, A2, B, C, D, F1, F2, G, H, J, and K. HIV-2 infection is endemicto West Africa. It generally takes longer to progress to symptomatic HIV/AIDS and has a lower mortality rate than HIV-1 infection.
[0119] In some embodiments, the HIV is HIV-1.
[0120] In some embodiments, the HIV is HIV-1 M group.
[0121] In some embodiments, the HIV is HIV-1 M group subtype A1.
[0122] In some embodiments, the HIV is HIV-1 M group subtype A2.
[0123] In some embodiments, the HIV is HIV-1 M group subtype B.
[0124] In some embodiments, the HIV is HIV-1
M group subtype C.
[0125] In some embodiments, the HIV is HIV-1 M group subtypeD.
[0126] In some embodiments, the HIV is HIV-1 M group subtypeF1.
[0127] In some embodiments, the HIV is HIV-1 M group subtypeF2.
[0128] In some embodiments, the HIV is HIV-1
M group subtype G.
[0129] In some embodiments, the HIV is HIV-1 M group subtype H.
[0130] In some embodiments, the HIV is HIV-1 M group subtype J.
[0131] In some embodiments, the HIV is HIV-1 M group subtype K.
[0132] In some embodiments, the HIV is HIV-1 N Group.
[0133] In some embodiments, the HIV is HIV-1 O Group.
[0134] In some embodiments, the HIV is HIV-1 P Group.
[0135] In some embodiments, the HIV is HIV-2.
[0136] HIV enters the central nervous system (CNS) early in the course of the infection and causes several important CNS conditions over the course of the disease, such as HIV encephalopathy and AIDS dementia complex. As part of the acute HIV syndrome during séroconversion, patients may expérience HIV encephalopathy. HIV-associated progressive encephalopathy (HPE) is a syndrome complex with cognitive, motor, and behavioral features seen in children. Prior to the advent of highly active antirétroviral therapy (HAART), dementia was a common source of morbidity and mortality in HIV-infected patients. It was usually observed in the late stages of AIDS, when CD4(+) lymphocyte counts fall below 200 cells/mL, and was seen in up to 50% of patients prior to their deaths. In 1986, the term AIDS dementia complex (ADC) was introduced to describe a unique constellation of neurobehavioral findings. HIV associated neurocognitive disorder (HAND) encompasses a hierarchy of progressively more severe patterns of neurological involvement. It can range from asymptomatic neurocognitive impairment (ANI) to minor neurocognitive disorder (MND) to more severe HIVassociated dementia (HAD) (also called AIDS dementia complex [ADC] or HIV encephalopathy). ADC is considered a single entity with a broad and varied spectrum of clinical manifestations and severity. ADC is characterized by cognitive, motor, and behavioral features in adults, usually those with advanced AIDS. With the advent of HAART, a less severe dysfunction, minor cognitive motor disorder (MCMD), has become more common than ADC. The overall psychosocial and emotional burden on the family and friends of patients with HIV dementia is tremendous, far beyond that of a cognitively intact patient with AIDS. Patients with cognitive difficulties hâve problems with compliance and adhérence to their médication regimen. Because of their neuropsychiatrie problems, these patients are likely to be less inhibited and are more prone to HIV-related risk behavior (e.g., unprotected intercourse), and they therefore pose a greater risk of transmission of the virus. In addition to HIV itself, other causes of neurologie complications in HIV-infected individuals include opportunistic infections, tumors, and antirétroviral drugs. Other neurologie complications that arise from primary HIV infection include vacuolar myelopathy, peripheral neuropathies, and polymyositis.
[0137] In some embodiments, the HIV-related disorder is an opportunisme infection selected from: candidiasis, coccidioidomycosis, cryptococcosis, cryptosporidiosis, cytomégalovirus, herpes simplex virus, herpes zoster, histoplasmosis, isosporiasis, mycobacterium avium complex, pneumocystis pneumonia, bacterial pneumonia, progressive multifocal leukoencephalopathy Salmonella, toxoplasmosis, and tuberculosis.
[0138] In some embodiments, the HIV-related disorder is an AIDS-related cancer selected from: cervical cancer, Kaposi sarcoma, and lymphomas.
[0139] In some embodiments, the HIV-related disorder is an AIDS-defining illnesses selected from: candidiasis ofthe esophagus, bronchi, trachea, or lungs, invasive cervical cancer, disseminated or extrapulmonary coccidioidomycosis, extrapulmonary cryptococcosis, chronic intestinal cryptosporidiosis, cytomégalovirus disease (other than liver, spleen, or nodes), cytomégalovirus retinitis with loss of vision, HIV related-encephalopathy, herpes simplex (with chronic ulcers, bronchitis, pneumonitis, oresophagitis), disseminated or extrapulmonary histoplasmosis, chronic intestinal isosporiasis, Kaposi sarcoma, Burkitt's lymphoma, immunoblastic lymphoma, primary lymphoma of brain, disseminated or extrapulmonary mycobacterium avium complex or M. kansasii, pulmonary or extrapulmonary mycobacterium tuberculosis, disseminated or extrapulmonary mycobacterium species, pneumocystis jiroveci pneumonia, récurrent pneumonia, progressive multifocal leukoencephalopathy, récurrent salmonella septicemia, toxoplasmosis of brain, and wasting syndrome due to HIV.
[0140] In some embodiments, the HIV-related disorder is a neurological disorder. [0141] In some embodiments, the neurological disorder is selected from: AIDS dementia complex, AIDS-induced encephalopathy, HIV encephalopathy, HIV-associated progressive encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, HIV-associated dementia, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis.
[0142] In some embodiments, the neurological disorder is AIDS dementia complex.
[0143] In some embodiments, the neurological disorder is AIDS-induced encephalopathy. [0144] In some embodiments, the neurological disorder is HIV encephalopathy.
[0145] In some embodiments, the neurological disorder is HIV-associated progressive encephalopathy.
[0146] In some embodiments, the neurological disorder is HIV-associated neurocognitive disorder.
[0147] In some embodiments, the neurological disorder is asymptomatic neurocognitive impairment.
[0148] In some embodiments, the neurological disorder is minor neurocognitive disorder. [0149] In some embodiments, the neurological disorder is minor cognitive motor disorder. [0150] In some embodiments, the neurological disorder is vacuolar myelopathy.
[0151] In some embodiments, the neurological disorder is peripheral neuropathy.
[0152] In some embodiments, the neurological disorder is polymyositis.
[0153] The association of a compound, or a pharmaceutically acceptable sait thereof, described herein and an antiviral agent in a composition may be physical or non-physical. Examples of physically associated compositions include: compositions (e.g. unitary formulations) comprising a compound, or pharmaceutically acceptable sait thereof, described herein and an antiviral agent in admixture (for example within the same unit dose); compositions comprising material in which a compound, or pharmaceutically acceptable sait thereof, described herein and an antiviral agent are chemically/physicochemically linked (for example by crosslinking, molecular agglomération or binding to a common vehicle moiety); compositions comprising material in which a compound, or pharmaceutically acceptable sait thereof, described herein and an antiviral agent are chemically/physicochemically co-packaged (for example, disposed on or within lipid vesicles, particles (e.g. micro- or nanoparticles) or émulsion droplets); and pharmaceutical kits, pharmaceutical packs or patient packs in which a compound, or pharmaceutically acceptable sait thereof, described herein and an antiviral agent are copackaged or co-presented (e.g. as part of an array of unit doses).
[0154] Examples of non-physically associated compositions include: material (e.g. a non-unitary formulation) comprising a compound, or pharmaceutically acceptable sait thereof, described herein or an antiviral agent together with instructions for the extemporaneous association ofthe compound, or pharmaceutically acceptable sait thereof, described herein and the antiviral agent to form a physical association ofthe two; material (e.g. a non-unitary formulation) comprising a compound, or pharmaceutically acceptable sait thereof, described herein or an antiviral agent together with instructions for adjunctive therapy with the compound, or pharmaceutically acceptable sait thereof, described herein and the antiviral agent; material comprising a compound, or pharmaceutically acceptable sait thereof, described herein or an antiviral agent with instructions for administration to a patient population in which the other ofthe compound, or pharmaceutically acceptable sait thereof, described herein or the antiviral agent hâve been (or are being) administered; and material comprising a compound, or pharmaceutically acceptable sait thereof, described herein or an antiviral agent in an amount or in a form which is specifically adapted for use in combination with the other ofthe compound, or pharmaceutically acceptable sait thereof, described herein or the antiviral.
[0155] Also provided are packaged compositions. Such packaged compositions include a pharmaceutical composition comprising at least one compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent and instructions for using the composition to treat a subject (typically a human patient). In some embodiments, the instructions are for using the pharmaceutical composition to treat a subject suffering an HIVrelated disorder. In some embodiments, the instructions are for using the pharmaceutical composition to treat a subject suffering an HIV-related neurological disorder. The packaged pharmaceutical composition can include providing prescribing information; for example, to a patient or health care provider, or as a label in a packaged pharmaceutical composition. Prescribing information may include for example efficacy, dosage and administration, contraindication and adverse reaction information pertaining to the pharmaceutical composition. [0156] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein and the antiviral agent are: a) in admixture; b) chemically/physicochemically linked; c) chemically/physicochemically co-packaged; ord) unmixed but co-packaged orco-presented.
[0157] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein and the antiviral agent are in admixture.
[0158] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein and the antiviral agent are chemically/physicochemically linked. [0159] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein and the antiviral agent are chemically/physicochemically copackaged.
[0160] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein and the antiviral agent are unmixed but co-packaged or copresented.
[0161] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein and the antiviral agent are co-packaged in a single container or in a plurality of containers within a single outer package.
[0162] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein is administered before the antiviral agent.
[0163] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein is administered after the antiviral agent.
[0164] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein and the antiviral agent are administered simultaneously.
[0165] In some embodiments, the antiviral agent and the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein, are administered simultaneously in a unitary formulation.
[0166] In some embodiments, the antiviral agent and the compound of Formula I, or a pharmaceutically acceptable sait thereof, described herein, are administered simultaneously in different formulations.
[0167] In some embodiments, the antiviral agent and the compound of Formula I or a pharmaceutically acceptable sait thereof, described herein are in a co-packaged drug product. [0168] In general, the compound, or pharmaceutically acceptable sait thereof, described herein and the antiviral agent will be administered in therapeutically effective amounts by any of the accepted modes of administration for agents that serve similar utilities. The actual amounts of the compound, or pharmaceutically acceptable sait thereof, described herein and the antiviral agent, i.e., the active ingrédients, will dépend upon numerous factors such as the severity ofthe disease to be treated, the âge and relative health of the subject, the potency ofthe compound used, the route and form of administration, and other factors well know to the skilled artisan. The active ingrédients can be administered at least once a day, such as once or twice a day.
[0169] In some embodiments, the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent are administered as pharmaceutical compositions. Accordingly, provided are pharmaceutical compositions comprising a compound, or a pharmaceutically acceptable sait thereof, described herein and/or an antiviral agent, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients.
[0170] Pharmaceutically acceptable vehicles must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal being treated. The vehicle can be inert or it can possess pharmaceutical benefits. The amount of vehicle employed in conjunction with the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent is sufficient to provide a practical quantity of material for administration per unit dose ofthe compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent.
[0171] Exemplary pharmaceutically acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose and its dérivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnésium stéarate; calcium sulfate; synthetic oils; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; polyols such as propylene glycol, glycérine, sorbitol, mannitol, and polyethylene glycol; alginic acid; phosphate buffer solutions; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonie saline; and phosphate buffer solutions.
[0172] Optional active agents may be included in a pharmaceutical composition, which do not substantially interfère with the activity of the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent.
[0173] Effective concentrations of the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent are mixed with a suitable pharmaceutically acceptable vehicle. In instances in which the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent exhibits insufficient solubility, methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate.
[0174] Upon mixing or addition ofthe compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent, the resulting mixture may be a solution, suspension, émulsion orthe like. The form ofthe resulting mixture dépends upon a numberof factors, including the intended mode of administration and the solubility ofthe compound, or pharmaceutically acceptable sait thereof, described herein and the antiviral agent in the chosen vehicle. The effective concentration sufficient for ameliorating the symptoms of the disease treated may be empirically determined.
[0175] The compound, or pharmaceutically acceptable sait thereof, described herein and the antiviral agent may be administered orally, topically, parenterally, intravenously, by intramuscular injection, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations.
[0176] Pharmaceutical compositions may be formulated for oral use, such as for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, émulsions, hard or soft capsules, orsyrups or élixirs. Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically élégant and palatable préparations. In some embodiments, oral pharmaceutical compositions contain from 0.1 to 99% of a compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent. In some embodiments, oral pharmaceutical compositions contain at least 5% (weight %) of a compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent. Some embodiments contain from 25% to 50% or from 5% to 75 % of a compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent.
[0177] Orally administered pharmaceutical compositions also include liquid solutions, émulsions, suspensions, powders, granules, élixirs, tinctures, syrups, and the like. The pharmaceutically acceptable carriers suitable for préparation of such compositions are well known in the art. Oral pharmaceutical compositions may contain preservatives, flavoring agents, sweetening agents, such as sucrose or saccharin, taste-masking agents, and coloring agents. [0178] Typical components of carriers for syrups, élixirs, émulsions and suspensions include éthanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. Syrups and élixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such pharmaceutical compositions may also contain a demulcent. [0179] The compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent can be incorporated into oral liquid préparations such as aqueous or oily suspensions, solutions, émulsions, syrups, or élixirs, for example. Moreover, pharmaceutical compositions containing a compound, or pharmaceutically acceptable sait thereof, described herein and/or an antiviral agent can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid préparations can contain conventional additives, such as suspending agents (e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stéarate gel, and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monooleate, or acacia), non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p-hydroxybenzoate and sorbic acid).
[0180] Fora suspension, typical suspending agents include methylcellulose, sodium carboxymethyl cellulose, Avicel RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate.
[0181] Aqueous suspensions contain the pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing orwetting agents; may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stéarate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol substitute, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan substitute. The aqueous suspensions may also contain one or more preservatives, for example ethyl, orn-propyl p-hydroxybenzoate.
[0182] Oily suspensions may be formulated by suspending the active ingrédients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a minerai oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral préparations. These pharmaceutical compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
[0183] Pharmaceutical compositions may also be in the form of oil-in-water émulsions. The oily phase may be a vegetable oil, for example olive oil or peanut oil, or a minerai oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products ofthe said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
[0184] Dispersible powders and granules suitable for préparation of an aqueous suspension by the addition of water provide the active ingrédient in admixture with a dispersing orwetting agent, suspending agent and one or more preservatives. Suitable dispersing orwetting agents and suspending agents are exemplified by those already mentioned above.
[0185] Tablets typically comprise conventional pharmaceutically acceptable adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnésium stéarate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics ofthe powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, can be useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The sélection of carrier components often dépends on secondary considérations like taste, cost, and shelf stability.
[0186] Such pharmaceutical compositions may also be coated by conventional methods, typically with pH ortime-dependent coatings, such that the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit® coatings, waxes and shellac.
[0187] Pharmaceutical compositions for oral use may also be presented as hard gelatin capsules wherein the active ingrédient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingrédient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
[0188] Pharmaceutical compositions may be in the form of a stérile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that hâve been mentioned above. The stérile injectable préparation may also be stérile injectable solution or suspension in a non-toxic parentally acceptable vehicle, for example as a solution in 1,3-butanediol. Among the acceptable vehicles that may be employed are water, Ringeris solution, and isotonie sodium chloride solution. In addition, stérile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be useful in the préparation of injectables.
[0189] The compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent may be administered parenterally in a stérile medium. Parentéral administration includes subeutaneous injections, intravenous, intramuscular, intrathecal injection or infusion techniques. The compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle. In many pharmaceutical compositions for parentéral administration the carrier comprises at least 90% by weight of the total composition. In some embodiments, the carrier for parentéral administration is chosen from propylene glycol, ethyl oleate, pyrrolidone, éthanol, and sesame oil.
[0190] The compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent may also be administered in the form of suppositories for rectal administration of the drug. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary températures but liquid at rectal température and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
[0191] The compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye. Topical pharmaceutical compositions may be in any form including, for example, solutions, creams, ointments, gels, lotions, milks, cleansers, moisturizers, sprays, skin patches, and the like.
[0192] Such solutions may be formulated as 0.01% -10% isotonie solutions, pH 5-7, with appropriate salts. The compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent may also be formulated for transdermal administration as a transdermal patch.
[0193] Topical pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent can be admixed with a variety of carrier materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantoin, glycérine, vitamin A and E oils, minerai oil, propylene glycol, PPG-2 myristyl propionate, and the like.
[0194] Other materials suitable for use in topical carriers include, for example, émollients, solvents, humectants, thickeners and powders. Examples of each of these types of materials, which can be used singly or as mixtures of one or more materials, are as follows:
[0195] Représentative émollients include stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, minkoil, cetyl alcohol, iso-propyl isostearate, stearic acid, iso-butyl palmitate, isocetyl stéarate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-n-butyl sebacate, iso-propyl myristate, iso-propyl palmitate, iso-propyl stéarate, butyl stéarate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum, minerai oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, and myristyl myristate;
propellants, such as propane, butane, iso-butane, dimethyl ether, carbon dioxide, and nitrous oxide; solvents, such as ethyl alcohol, methylene chloride, iso-propanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran; humectants, such as glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, and gelatin; and powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloïdal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnésium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, and ethylene glycol monostearate.
[0196] The compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent may also be topically administered in the form of liposome delivery Systems, such as small unilamellarvesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholestérol, stearylamine or phosphatidylcholines.
[0197] Other pharmaceutical compositions useful forattaining systemic delivery ofthe compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent include sublingual, buccal and nasal dosage forms. Such pharmaceutical compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methylcellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
[0198] Pharmaceutical compositions for inhalation typically can be provided in the form of a solution, suspension or émulsion that can be administered as a dry powder or in the form of an aérosol using a conventional propellant (e.g., dichlorodifluoromethane or trichlorofluoromethane).
[0199] The pharmaceutical compositions may also optionally comprise an activity enhancer. The activity enhancer can be chosen from a wide variety of molécules that function in different ways to enhance or be independent oftherapeutic effects ofthe compound, orpharmaceutically acceptable sait thereof, described herein and/or the antiviral agent. Particular classes of activity enhancers include skin pénétration enhancers and absorption enhancers.
[0200] Pharmaceutical compositions may also contain additional active agents that can be chosen from a wide variety of molécules, which can function in different ways to enhance the therapeutic effects of the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent. These optional other active agents, when présent, are typically employed in the pharmaceutical compositions at a level ranging from 0.01% to 15%. Some embodiments contain from 0.1% to 10% by weight ofthe composition. Otherembodiments contain from 0.5% to 5% by weight ofthe composition.
[0201] In ail of the foregoing the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent can be administered in combination with other active agents.
[0202] When used in combination with one or more additional pharmaceutical agent or agents, the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent may be administered priorto, concurrently with, orfollowing administration ofthe additional pharmaceutical agent or agents.
[0203] The dosages ofthe compounds described herein dépend upon a variety of factors including the particularsyndrome to be treated, the severity ofthe symptoms, the route of administration, the frequency ofthe dosage interval, the particular compound utilized, the efficacy, toxicology profile, pharmacokinetic profile ofthe compound, and the presence of any deleterious side-effects, among other considérations.
[0204] The compound, or pharmaceutically acceptable sait thereof, described herein and the antiviral agent are typically administered at dosage levels and in a manner customary for KMO inhibitors and antiviral agents respectively. For example, the compound, or pharmaceutically acceptable sait thereof, described herein and/or the antiviral agent can be administered, in single or multiple doses, by oral administration at a dosage level of generally 0.001-100 mg/kg/day, for example, 0.01-100 mg/kg/day, such as 0.1-70 mg/kg/day, for example, 0.5-10 mg/kg/day. Unit dosage forms can contain generally 0.01-1000 mg of a compound, or pharmaceutically acceptable sait thereof, described herein and/or an antiviral agent for example, 0.1-50 mg of at least one compound, or pharmaceutically acceptable sait thereof, described herein and/or an antiviral agent. For intravenous administration, the at least one compound, or pharmaceutically acceptable sait thereof, described herein and/or an antiviral agent can be administered, in single or multiple dosages, at a dosage level of, for example, 0.001-50 mg/kg/day, such as 0.001-10 mg/kg/day, for example, 0.01-1 mg/kg/day. Unit dosage forms can contain, for example, 0.1-10 mg of a compound, or pharmaceutically acceptable sait thereof, described herein and/or an antiviral agent.
[0205] In carrying out the procedures ofthe methods described herein, it is of course to be understood that reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include ail related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will hâve sufficient knowledge of such Systems and méthodologies so as to be able, without undue expérimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.
EXAMPLES
The compounds, pharmaceutically acceptable salts and prodrugs thereof, described herein, compositions, and methods described herein are further illustrated by the following nonlimiting examples.
As used herein, the following abbreviations hâve the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.
DCM | dichloromethane | |
DMF | = | N,N-dimethylformamide |
DMSO | = | dimethylsulfoxide |
EtOAc | = | ethyl acetate |
g | = | g ram |
hr | = | hour |
hrs | = | hours |
LC/MS | = | liquid chromatography / mass spectrometry |
mg | = | milligram |
min | = | minutes |
mL | = | milliliter |
mmol | = | millimoles |
mM | = | millimolar |
nm | = | nanometer |
rt | = | room température |
TBME | = | t-butyl methyl ether |
THF | = | tetrahydrofuran |
pL | = | microliter |
pM | = | micromolar |
1g/1mL | = | 1 vol |
Experimental [0206] Commercially available reagents and solvents (HPLC grade) were used without further purification.
[0207] Thin-layer chromatography (TLC) analysis was performed with Kieselgel 60 F254 (Merck) plates and visualized using UV light. Microwave reactions were carried out using CEM focused microwaves.
[0208] Analytical HPLC-MS was performed on Agilent HP1100 and Shimadzu 2010, Systems using reverse phase Atlantis dC18 columns (5 pm, 2.1 x 50 mm), gradient 5-100% B ( A = water/0.1% formic acid, B= acetonitrile/0.1% formic acid) over 3 minutes, injection volume 3 pL, flow =1.0 mL/min. UV spectra were recorded at 215 nm using a Waters 2487 dual wavelength UV detectororthe Shimadzu 2010 system. Mass spectra were obtained over the range m/z 150 to 850 at a sampling rate of 2 scans per second using Waters ZMD and over m/z 100 to 1000 at a sampling rate of 2 Hz using Electrospray Ionisation, by a Shimadzu 2010 LC-MS system, or analytical HPLC-MS was performed on Agilent HP1100 and Shimadzu 2010, Systems using reverse phase Water Atlantis dC18 columns (3 pm, 2.1 χ 100 mm), gradient 5-100% B (A = water/0.1% formic acid, B= acetonitrile/0.1% formic acid) over 7 min, injection volume 3pL, flow = 0.6 mL/min. UV spectra were recorded at 215 nm using a Waters 2996 photo diode array or on the Shimadzu 2010 system. Mass spectra were obtained over the range m/z 150 to 850 at a sampling rate of2 scans per second using Waters ZQ and over m/z 100 to 1000 ata sampling rate of 2 Hz using Electrospray Ionisation, by a Shimadzu 2010 LC-MS system. Data were integrated and reported using OpenLynx and OpenLynx Browser software or via Shimadzu PsiPort software.
Example 1
Reaction Scheme 1
Stage 1
Stage 2
N
R2 [0209] Referring to Reaction Scheme 1, Stage 1, to a stirred suspension of dichloropyrimidine (1 eq) in 1,4-dioxane (15 vol) was added boronic acid (0.7 eq) and Pd(PPh3)4 (0.025 eq). A 2 M K2CO3 solution (7.5 vol) was added to the resulting mixture, which was heated at 90 °C overnight under an atmosphère of N2. The reaction mixture was cooled to room température and concentrated in vacuo. The residue was dissolved in EtOAc:water (1:1) (100 vol) and the resulting solution filtered through celite. The organic layer was separated and the aqueous layer further extracted with EtOAc (50 vol). The combined organic layers were washed with saturated aqueous NaCI (20 vol), dried over Na2SÜ4, filtered and the solvent removed in vacuo. The resulting residue was purified by flash column chromatography (eluent: [0:1 to 1:19] EtOAc:heptane) to afford the required target compounds.
[0210] Referring to Reaction Scheme 1, Stage 2, 4-chloro-6-substituted-phenyl-pyrimidine (1 eq), PdCI2(dppf).DCM (0.05 eq) and triethylamine (2 eq) were suspended in degassed MeOH (50 vol) in a bomb fitted with a magnetic stirrer bar. The atmosphère in the reaction vessel was replaced with N2 by successive évacuation and charging with N2 gas (this process was repeated three times). The bomb was then flushed with CO by successive charging with CO and évacuation. The vessel was pressurized to 5 bar of CO and heated at 50 °C with stirring for 5 hours. The reaction vessel was allowed to cool to room température before venting CO and flushing with N2. The reaction mixture was concentrated in vacuo and the resulting residue dissolved in EtOAc (30 vol) and water (30 vol). The solution was filtered through cotton wool and the organic layer was separated, washed with saturated aqueous NaCI (15 vol), dried over Na2SO4, filtered and concentrated under reduced pressure. Purification by flash column chromatography (eluent: [0:1 to 1:9] EtOAc:heptane) yielded the target compounds.
[0211] Referring to Reaction Scheme 1, Stage 3, 6-substituted-phenyl-pyrimidine-4-carboxylic acid methyl ester (1 eq) was suspended in MeOH (20 vol), 1 M NaOH solution (20 vol) and stirred at room température for 4 hours. The reaction mixture was acidified with 2 M HCl.
Soluble products were extracted with DCM (2 χ 20 vol) and the combined organic layers were dried over MgSO4, filtered and concentration under reduced pressure afforded the target compounds. Insoluble products were filtered, washed with water (3x10 vol) and heptane (3 χ 10 vol) before drying in vacuo to yield the target compounds.
[0212] The following compounds were prepared substantially as described above.
Compound No. | Chemical Structure | Molecular Weight | Mass Spec Resuit |
1 | N^N 0 /O | 264.67 | [M+H]+ = 265/267, 100% @ rt = 3.53 and 3.70 min |
16 | N^N F | 252.63 | [M+H]+ = 253, 100% @ rt = 4.06 min |
17 | N^N Cl | 252.63 | [M+H]+= 253, 100% @rt = 3.92-4.23 min |
18 | N^N ci^Y 0 Cl | 269.09 | [M+H]+= 269, 100%@rt = 4.04 min |
19 | N^N F^V ° F | 236.18 | [M+H]+= 237, 100% @ rt = 3.74 min |
20 | N^N Cl | 264.67 | [M+H]+= 265, 100%@rt = 3.73-4.10 min |
Example 2
Reaction Scheme 2
[0213] Referring to Reaction Scheme 2, Stage 1, R-OH (1 eq) in DCM (70 vol) at O °C was added dibromo triphenyl phosphorane (1.2 eq). The reaction mixture was allowed to warm to room température and stirred for 16 hrs. The solvent removed in vacuum. DCM (10 vol) was added to the reaction mixture. The precipitate was filtered to afford the target compound. The crude mixture was used in the next step without further purification.
[0214] Referring to Reaction Scheme 2, Stage 2, R-Br (1.1 eq) in DMF (15 vol) were added 2chloro-4-iodophenol (1 eq) and CS2CO3 (2.5 eq). The reaction mixture was refluxed for 3 hours under nitrogen. The reaction mixture was allowed to cool to room température and EtOAc (40 vol) and aq ammonia (40 vol) were added. The organic layer was separated and the aqueous layer further extracted with EtOAc (50 vol). The combined organic layers were washed with saturated aqueous NaCI (20 vol), dried over Na2CO3, filtered and the solvent removed in vacuo. The resulting residue was purified by flash column chromatography (eluent: [3:1]
EtOAc:heptane) to afford the required target compound.
[0215] Referring to Reaction Scheme 2, Stage 3, to a stirred suspension of 4- subtituted-3 chloro-iodobenzene (1 eq) in degassed DMF (15 vol) was added bis-diborane (1.05 eq), Pd(OAc)2 (0.04 eq) and KOAc (3.0 eq). The reaction mixture was heated at 90 °C for 5 hrs under an atmosphère of N2. The reaction mixture was cooled to room température and filtered through celite then concentrated in vacuo to give crude product. Crude was used in the next step without further purification.
[0216] Referring to Reaction Scheme 2, Stage 4, to a stirred suspension of dichloropyrimidine (1 eq) in 1,4-dioxane (90vol) was added boronic ester (1.0 eq) and Pd(PPh3)4 (0.03eq). A 2 M K2CO3 (3 eq) solution was added to the resulting mixture, which was heated at 90 °C for 16 hrs under an atmosphère of N2. The reaction mixture was cooled to room température and concentrated in vacuo. The residue was dissolved in EtOAciwater (1:1) (100 vol) and the resulting solution filtered through celite. The organic layer was separated and the aqueous layer further extracted with EtOAc (50 vol). The combined organic layers were washed with saturated aqueous NaCI (20 vol), dried over Na2SO4, filtered and the solvent removed in vacuo. The resulting residue was purified by flash column chromatography (eluent: [3:1] EtOAc:heptane) to afford the required target compound.
[0217] Referring to Reaction Scheme 2, Stage 5, 4-chloro-6-substituted-phenyl-pyrimidine (1 eq), PdCI2(dppf).DCI\/l (0.05 eq) and triethylamine (2 eq) were suspended in degassed MeOH (50 vol) in a bomb fïtted with a magnetic stirrer bar. The atmosphère in the reaction vessel was replaced with N2 by successive évacuation and charging with N2 gas (this process was repeated three times). The bomb was then flushed with CO by successive charging with CO and évacuation. The vessel was pressurized to 5 bar of CO and heated at 50 °C with stirring for 16 hours. The reaction vessel was allowed to cool to room température before venting CO and flushing with N2. The reaction mixture was concentrated in vacuo and the resulting residue dissolved in EtOAc (30 vol) and water (30 vol). The organic layer was separated, washed with saturated aqueous NaCI (15 vol), dried over Na2SO4, filtered and concentrated under reduced pressure. Purification by re-crystallization using MeOH yielded the target compound.
[0218] Referring to Reaction Scheme 2, Stage 6, 6-substituted-phenyl-pyrimidine-4-carboxylic acid methyl ester (1 eq) was suspended in THF (20 vol), 2 M NaOH (2.5 eq) and stirred at room température for 4 hours. Solvent (THF) was removed and reaction mixture was acidified with 2 M HCl. Resulting solid was filtered and was with water to give desired product.
[0219] The following compounds were prepared substantially as described above.
Compound No. | Chemical Structure | Molecular Weight | Mass Spec Resuit |
2 | N^N Cl | 292.72 | [M+H]+= 293/295, 100% @ rt = 4.18 min |
3 | An A0JÇAj Cl | 318.76 | [M+H]+=319, 100% @rt = 4.61 min |
Compound No. | Chemical Structure | Molecular Weight | Mass Spec Resuit |
4 | ΝΆ Cl | 306.75 | [M+H]+ = 307/309, 100% @ rt = 4.37 min |
5 | N^N AV1 Cl | 306.75 | [M+H]+ = 307/309, 100% @ rt = 4.37 min |
6 | nA \Çtï Cl | 290.71 | [M+H]+= 291/293, 100% © rt = 3.93 min |
7 | N^N AVS Cl | 304.79 | [M+H]+= 305/307, 100% @ rt = 4.20 min |
8 | An V Cl | 302.72 | [M-Naf = 303/305, 100% © rt = 4.14 min |
Example 3
Reaction Scheme 3
[0220] Referring to Reaction Scheme 3, Stage 1. Triethylamine (19.01 mL, 146.92 mmol) was added dropwise to a solution of diethyl but-2-ynedioate (25.0 g, 146.92 mmol) and formamidine hydrochloride (11.83 g, 146.92 mmol) in acetonitrile (500 mL). The resulting red solution was heated at 80 °C for 2.5 hours. After this time the reaction mixture was cooled to 5 °C using a saturated NaCI/ice bath and the reaction was stirred at this température for 25 minutes. After this time the resulting solid precipitate was collected under suction and dried on a sinterfunnel for 30 minutes under vacuum at room température before drying in the vacuum oven at room température for 3 hours to give the desired compound (21.3 g, 86% yield) as a pale brown solid. Tr = 0.85 min (3.5 minute method) mlz (ES+) [M+H]+ 169.
[0221] Referring to Reaction Scheme 3, Stage 2. Ethyl 6-hydroxypyrimidine-4-carboxylate (21.3 g, 126.67 mmol) was dissolved in dry DMF (100 mL) in a 2 neck flask. The flask was purged with a stream of nitrogen while cooling in an ice bath for 10 minutes. After this time, thionyl chloride (15.6 mL, 215.6 mmol) was added dropwise over 20 minutes, before being warmed to room température and stirred under a nitrogen atmosphère for 2 hours. After this time, the reaction mixture was carefully poured onto ~100 mL ice water. TBME (100 mL) was added, the organic layer was separated and the aqueous extracted with further TBME (3 x 100 mL). The combined organic layers were washed consecutively with water (2 x 100 mL), and brine (100 mL) before being dried (MgSO4), filtered and concentrated to give the desired compound (8.8 g, 37% yield) as a light orange powder. δΗ (500 MHz, DMSO) 9.23 (d, J= 0.95 Hz, 1 H), 8.16 (d, J = 1.10 Hz, 1 H), 4.39 (q, J=7.09 Hz, 2 H), 1.34 (t, J=7.17 Hz, 3 H). Tr= 1.43 min (3.5 minute method) mlz (ES+) [M+H]+ 187 [0222] Referring to Reaction Scheme 3, Stage 3. Tripotassium phosphate (1.12 g, 5.63 mmol) was added in one portion to a stirred solution ofthe dioxaborolane (3.75 mmol) and ethyl 6chloropyrimidine-4-carboxylate (0.7 g, 3.75 mmol) in DMF (20 mL). The mixture was degassed with nitrogen for 5 minutes, after which time Pd(dppf)2Cl2 (0.14 g, 0.19 mmol) was added in one portion, the mixture was then heated to 80 °C and stirred at this température for 16 hours under a nitrogen atmosphère. After this time the reaction mixture was cooled to room température and partitioned between ethyl acetate (200 mL) and water (100 mL). The organic layer was separated, washed sequentially with water (100 mL) then brine (100 mL) before being dried (MgSCL), filtered and concentrated. The resulting brown solid was purified by flash column chromatography (elution: 40% EtOAc, 60% Heptane) to give the desired compound.
[0223] Referring to Reaction Scheme 3, Stage 4. NaOH (2 M solution, 0.63 mL, 1.27 mmol) was added in one portion to a stirred solution of ethyl 6-substituted pyrimidine-4-carboxylate (1.15 mmol) in THF (10 mL) and the mixture was stirred at room température for 16 hours before being heated to reflux for 2 hours. After this time, the reaction mixture was cooled to room température and the resulting precipitate was collected by filtration, washed with THF (20 mL) before being dried under vacuum to give the desired compound.
[0224] The following compounds were prepared substantially as described above.
Compound No. | Chemical Structure | Molecular Weight | Mass Spec Resuit |
9 | N^N /oJU ° Cl | 278.04 | [M+H]+= 279/281, 100% @ rt = 3.65 min |
Example 4
Reaction Scheme 4
[0225] Referring to Reaction Scheme 4, Stage 1. Méthylmagnésium bromide (1.4M in toluene/THF, 1.5 mL, 0.046 mol) was added drop wise over 1 hourto a cold (-78 °C), stirred solution of 4-bromo-2-chlorobenzaldehyde (5.0 g, 0.023 mol) in THF (100 mL) and the mixture was stirred at this température under a nitrogen atmosphère for 1 hour. After this time, the reaction mixture was allowed to warm to room température over 1 hour before being stirred for a further 1.5 hours. The reaction mixture was then cooled to 5 °C in an ice bath and stirred for 10 minutes before saturated ammonium chloride (40 mL) was added drop wise and stirring continued at this température for a further 10 minutes before being allowed to warm to room température. The resulting mixture was then extracted with ethyl acetate (1 χ 100 mL), the organic layer was washed sequentially with water (100 mL), and brine (100 mL) before being dried (MgSO4), filtered and concentrated. The resulting residue was purified by flash column chromatography (elution: 10% ethyl acetate, 90% heptanes) to give the desired compound (4.33 g, 81% yield) as a colourless oil. δΗ (500 MHz, DMSO) 7.64 (d, J=1.58 Hz, 1 H) 7.49 - 7.60 (m, 2 H) 5.47 (d, J= 3.00 Hz, 1 H) 4.96 (dd, J = 6.07, 2.60 Hz, 1 H) 1.28 (d, J = 6.31 Hz, 3 H).
[0226] Referring to Reaction Scheme 4, Stage 2. Sodium hydride (60% in oil, 0.38 g, 9.6 mmol) was added portion wise over 5 minutes to a cooled (0 °C), stirred solution of 1-(4-bromo-2chlorophenyl)ethan-1-ol (1.5 g, 6.4 mmol) in DMF (15 mL) and the reaction was stirred at this température for 20 minutes under a nitrogen atmosphère. After this time, methyl iodide (0.48 mL, 7.6 mmol) was added in one portion and the reaction mixture was allowed to warm to room température before being stirred for a further 18 hours. The reaction was quenched by the drop wise addition of water (15 mL) over 10 minutes and the resulting solution was extracted with ethyl acetate (2 χ 30 mL). The combined organic extracts were washed sequentially with water (100 mL) and brine (10 mL) before being dried (MgSCU), filtered and concentrated to give the desired compound (1.5 g, 99% yield) as a yellow oil. δΗ (500 MHz, DMSO) 7.71 (d, J =1.89 Hz, 1 H) 7.60 (dd, J =8.35, 1.89 Hz, 1 H) 7.39 (d, J =8.35 Hz, 1 H) 4.63 (q, J =6.46 Hz, 1 H) 3.16 (s, 3 H) 1.26-1.38 (m, 3 H).
[0227] Referring to Reaction Scheme 4, Stages 3, 4 & 5 were carried out as described in Reaction Scheme 3 [0228] The following compounds were prepared substantially as described above.
Compound No. | Chemical Structure | Molecular Weight | Mass Spec Resuit |
10 | N^N o ' Cl | 292.72 | [M+H]+= 293/295, 100% @ rt = 3.72 min |
Example 5 [0229] The following compounds may be prepared substantially as described above.
Compound No. | Chemical Structure | Chemical Name |
11 | N^N __O | 6-(3-chloro-4-(cyclopropoxymethyl)- phenyl)pyrimidine-4-carboxylic acid |
12 | N^N __O | 6-(3-chloro-4-(1-cyclopropoxyethyl)- phenyl)pyrimidine-4-carboxylic acid |
13 | N^N | 6-(4-chloro-3-cyclopropoxy- phenyl)pyrimidine-4-carboxylic acid |
Compound No. | Chemical Structure | Chemical Name |
14 | N^N Y | 6-(4-chloro-3-isopropoxy- phenyl)pyrimidine-4-carboxylic acid |
15 | N Y X | 6-(4-chloro-3-isobutoxy- phenyl)pyrimidine-4-carboxylic acid |
Example 6 [0230] A generalized procedure for monitoring L-Kynurenine (KYN) hydroxylation to form product 3-Hydroxy-Kynurenine (3OH-KYN) by LC/MS is described below. Product is quantified by multiple reaction monitoring using MS.
Key reagents:
Compound: Stock concentrations: 10 mM in 100% DMSO
Cell line: CHO GST HIS KMO cell line, 1E4 cells/well/100 pl_ in 96well cell plate
Substrate: L-Kynurenine (Sigma: Cat# K3750, stock concentration:
mM in 100 mM potassium phosphate buffer, pH 7.4)
Assay conditions:
Medium: | OptiMem (Reduced Sérum Medium Ix, +L-Glutamine + HEPES - Phénol Red; GIBCO: Cat# 11058) |
Assay Volume: | 200 pL |
Plate Format: | 96 well plate, transparent (Corning) |
Read-Out: | product (3OH-KYN) quantification using product spécifie MRM |
Reader: | LC/MS/MS |
Assay protocol:
o préparé serial dilution (factor 3) of compound in 100% DMSO (top concentration = 6.67 mM,
100% DMSO) [8 points: 6.67 mM; 2.22 mM; 0.74 mM; 0.247 mM; 0.082 mM; 0.027 mM; 0.009 mM; 0.003mM] o préparé 300-fold concentrated solution of each compound concentration (top concentration
22.22 pM, 0.3% DMSO) in OptiMem medium [22.2 pM; 7.41 pM; 2.47 pM; 0.82 pM; 0.27 pM; 0.09 pM; 0.03 pM; 0.01 pM] o préparé substrate ( 10 mM) at concentration of 1.1 mM in medium o medium of cell plate is drawed off o cells are washed with OptiMem (100 pL/well) and drawed off again o assay mix: 90 pL OptiMem/well + 90 pL compound/well of each concentration [final compound top concentration: 10 pM; 0.15% DMSO] [final compound bottom concentration: 0.004 pM; 0.15% DMSO] o pre-incubation: 30min at 37 °C o add 20pLwell ofthe 1.1 mM substrate solution (final assay concentration: 100 pM) o positive control: 200 pL OptiMem o négative control: 180 pL OptiMem + 20 pL 1.1 mM substrate o incubate ~24h at 37 °C o transfer 100 pL of each well in a transparent 96 well plate (Coming) o add 100 pL/well 10% trichloro acetic acid (TCA) in water o centrifugate plate for 3 min at 4000 rpm o detect product by LC/MS (injection of 50 pL/well; 2.5 fold overfill of the 20 pL sample loop)
Data analysis: ICso’s are calculated using automated fitting algorithm (A+ Analysis)
Example 7 [0231] A method of monitoring L-Kynurenine (KYN) hydroxylation to form product 3-HydroxyKynurenine (3OH-KYN) by LC/MS is described below. Product is quantified by multiple reaction monitoring.
Key reagents:
Compound: Stock concentrations: 10 mM in 100% DMSO
Enzyme: KMO enzyme prepared at Evotec via mitochondria isolation from CHOGST HIS KMO cells
Substrate: L-Kynurenine (Sigma: Cat# K3750) [stock concentration: 10 mM in 100 mM potassium phosphate buffer, pH
7.4]
Assay conditions:
Buffer: | 100 mM potassium phosphate, pH 7.4, 200pM NADPH, 0.4U/ml G6P-DH (Glucose 6-phosphate dehydrogenase), 3mM G6P (D-Glucose 6phosphate) |
Assay Volume: | 40 pL |
Plate Format: | 384 well plate, transparent (Matrix) |
Read-Out: | product (3OH-KYN) quantification using product spécifie MRM |
Reader: | LC/MS/MS |
Assay protocol:
o préparé serial dilution (factor 3) of compound in 100% DMSO (top concentration = 10 mM, 100% DMSO) [8 points: 10 mM; 3.33 mM; 1.11 mM; 0.37 mM; 0.12 mM; 0.04 mM; 0.0137 mM; 0.0045 mM, 0.0015 mM] o préparé 3.33 -fold concentrated solution of each compound concentration (top concentration 300μΜ, 3% DMSO)in assay buffer [concentrations: 300 μΜ; 100 μΜ; 33.3 μΜ; 11.1 μΜ; 3.70 ρΜ; 1.23 μΜ; 0.41 μΜ; 0.137 μΜ] ο préparé substrate (10 mM) at concentration of 1 mM in assay buffer o assay mix: 4 pL compound/well of each concentration + 24 pl_ assay buffer/well + 8 pl_ KMO human enzyme + 4 pL 1 mM substrate (final concentration = 100 pM) [final compound top concentration: 30 pM; 0.3% DMSO] [final compound bottom concentration: 0.0137 pM; 0.3% DMSO] o positive control: 4 pL 50 pM FCE28833 in assay buffer [0.5%DMSO] (final assay concentration = 5 pM) + 24 pL assay buffer/well + 8 pL KMO human enzyme + 4 pL 1 mM substrate (final concentration = 100 pM) o négative control: 28 pL assay buffer/well + 8 pL KMO human enzyme + 4 pL 1 mM substrate (final concentration = 100 pM) o incubate 400min at RT o add 40 pL/well 10% trichloro acetic acid in water to stop the assay and precipitate protein o centrifuge plate for 3 min at 4000 rpm o product détection by LC/MS (injection of 50 pL/well; 2.5 fold overfill of the 20 pL sample loop)
Data analysis: | ICso’s are calculated using automated fitting algorithm (A+ Analysis). |
Example 8 [0232] A method of monitoring L-Kynurenine (KYN) hydroxylation to form 3- HydroxyKynurenine (3OH-KYN) by LC/MS is described. Product is quantified by multiple reaction monitoring (MRM method).
Key reagents:
Compound: | Stock concentrations: 10 mM in 100% DMSO |
Enzyme: | KMO enzyme prepared at Evotec from mouse Iiver (4-6 weeks old) via mitochondria isolation as described in the literature |
Substrate: | L-Kynurenine (Sigma: Cat# K3750, stock concentration: 10 mM in 100 mM potassium phosphate buffer, pH 7.4) |
Assay conditions:
Buffer: | 100 mM potassium phosphate, pH 7.4, 200 μΜ NADPH, 0.4 U/mL G6P- DH (Glucose 6-phosphate Dehydrogenase), 3 mM G6P (D-Glucose 6phosphate) |
Assay Volume: | 40 pL |
Plate Format: | 384 well plate, transparent (Matrix) |
Read-Out: | product (3OH-KYN) quantification using product spécifie MRM |
Reader: | LC/MS/MS |
Assay protocol:
o préparé serial dilution (factor 3) of compound in 100% DMSO (top concentration = 10 mM, 100% DMSO) [8 points: 10 mM; 3.33 mM; 1.11 mM; 0.37 mM; 0.12 mM; 0.04 mM; 0.0137 mM; 0.0045 mM, 0.0015 mM] o préparé 3.33 -fold concentrated solution of each compound concentration (top concentration
300 μΜ, 3% DMSO) in assay buffer [concentrations: 300 μΜ; 100 μΜ; 33.3 μΜ; 11.1 μΜ; 3.70 μΜ; 1.23 μΜ; 0.41 μΜ; 0.137 μΜ] o préparé substrate (10 mM) at concentration of 1 mM in assay buffer o assay mix: 4 μΙ_ compound/well of each concentration + 24 pL assay buffer/well + 8 μΙ_ KMO mouse enzyme + 4 μΙ_ 1 mM substrate (final concentration = 100 μΜ) [final compound top concentration: 30 μΜ; 0.3% DMSO] [final compound bottom concentration: 0.0137 μΜ; 0.3% DMSO] o positive control: 4 μΙ_ 50μΜ FCE28833 in assay buffer, 0.5% DMSO [final assay concentration = 5μΜ] + 24 μΙ_ assay buffer/well + 8 μΙ_ KMO mouse enzyme + 4 μΙ_ 1 mM substrate [final concentration = 100 μΜ] o négative control: 28 μΙ_ assay buffer/well + 8 μΙ_ KMO mouse enzyme + 4 μΙ_ 1 mM substrate [final concentration = 100 μΜ] o incubate 40 min at RT o add 40 pL/well10% trichloro acetic acid in water to stop the assay and precipitate protein o centrifuge plate for 3 min at 4000 rpm o product détection by LC/MS (injection of20 pl_/well, 2 fold overfill ofthe 10 pL sample loop)
Data analysis: ICso’s are calculated using automated fitting algorithm (A+ Analysis).
Example 9 [0233] Using procedures similar to those described herein, the following compounds were assayed for activity.
lUPAC name | % Inhibition at 10 μΜ* |
6-(4-chloro-3-methoxy- phenyl)pyrimidine-4-carboxylic acid | 99.62 |
6-(3-chloro-4-isopropoxy- phenyl)pyrimidine-4-carboxylic acid | 100 |
6-(3-chloro-4-(cyclopentyloxy)- phenyl)pyrimidine-4-carboxylic acid | 97 |
(S)-6-(4-sec-butoxy-3-chlorophe nyl) py ri m i d i n e-4-carboxy I ic acid | 100 |
(R)-6-(4-sec-butoxy-3-chloro- phenyl)pyrimidine-4-carboxylic acid | 100 |
IUPAC name | % Inhibition at 10 μΜ* |
6-(3-chloro-4-cyclopropoxy- phenyl)pyrimidine-4-carboxylic acid | 100 |
6-(3-chloro-4-cyclobutoxy- phenyl)pyrimidine-4-carboxylic acid | 100 |
6-(3-chloro-4-(cyclopropylmethoxy)- phenyl)pyrimidine-4-carboxylic acid | 101 |
6-(4-chloro-3-fluoro-phenyl)pyrimidine- 4-carboxylic acid | 102.645 |
Example 10
MICRODIALYSIS PROCEDURE FOR MOUSE STUDIES [0234] Animais were anesthetized using isoflurane (2%, 800 mL/min 02). Bupivacain/epinephrine was used for local analgesia, finadyne or carprophen for peri-/postoperative analgesia. The animais were placed in a stereotaxic frame (Kopf instruments, USA). Ishaped probes (membrane: polyacrylonitrile, 3 mm exposed surface; Brainlink, the Netherlands) were inserted in the striatum. After surgery, animais were kept individually in cages; provided food and water ad libitum.
[0235] Experiments were performed one day after surgery. On the day of the experiment, the probes of the animais were connected with flexible PEEK tubing to a microperfusion pump (Harvard PHD 2000 Syringe pump, Holliston, MA or similar). The l-shaped microdialysis probes were perfused with aCSF containing 147 mM NaCI, 3.0 mM KCI, 1.2 mM CaCI2 and 1.2 mM MgCI2, at a flow rate of 1.5 pL/min. Microdialysis samples were collected at 20-minute intervals by an automated fraction collecter (820 Microsampler, Univentor, Malta or similar) into mini-vials already containing 10 pL 0.02 M formic acid (FA) and 0.04% ascorbic acid in ultrapurified H2O. At t = -30 min vehicle or KMO inhibitor were be administered, to ensure central and peripheral inhibition of KMO at the time of administration of kynurenine. At t = 0 vehicle or kynurenine were administered. Microdialysate samples were collected for 240 min after administration of kynurenine. Ail the dialysis samples were stored at -80 °C awaiting their analysis. Dialysate levels of any or ail of KP métabolites KYN, KYNA, 3-OH-KYN, AA and QA were quantified by LC-MS/MS at by Brains On-Line. After the experiment, the mice were sacrificed and terminal brain (striatum + cortex), liver, kidney, plasma and CSF samples were collected for analysis of KP métabolites. Levels of KP métabolites were measured in terminal brain (striatum + cortex), liver, kidney, plasma and CSF samples at Brains On-Line. Finally, levels of kynurenine and KMO inhibitors in dose formulation samples were quantified by Brains On-Line.
Example 11 [0236] A method of examining the modulation of KYN, KYNA, AA, and 3-HK via KMO inhibition with Compound 6 in striatum extracellular space is disclosed. Specifically, this experiment is aimed at demonstrating the dose dépendent différences in central KP métabolite (KYN, KYNA, AA, 3-HK) élévations between dosing of Compound 6 at various levels in an animal brain. Following the microdialysis procedure described herein, dialysate levels of KP métabolites KYN, KYNA, 3-HK, and AA were quantified by LC-MS/MS at by Brains On-Line.
[0237] When microdialysis after PO dosing Compound 6 at various dosage levels (3 mg/kg, 10 mg/kg, or 30 mg/kg) was performed, Compound 6 showed dose dépendent increases KYN (see FIG. 1), as well as protective métabolites KYNA (see FIG. 2) & AA (see FIG. 3) in mouse striatum, while there was little or no effect on harmful métabolite 3-HK (see FIG. 4).
Example 12 [0238] A method of examining the modulation of KP métabolites in HD animais similar to WT contrais is disclosed. Specifically, this experiment is aimed at demonstrating that Compound 6 modulâtes the différences in KYNA élévations in an animal brain. Following the microdialysis procedure described herein, dialysate levels of KP métabolite KYNA was quantified by LCMS/MS at by Brains On-Line.
[0239] When microdialysis after PO dosing of Compound 6 at either 3 mg/kg or 10 mg/kg was performed, it was shown that Compound 6 increases KYNA in both WT (see FIG. 5) and HD animais (see FIG. 6), with little différence between the two.
Example 13 [0240] A method of examining the pharmacodynamie effects of kynurenine (30 mg/kg, p.o.) and Compound 6 (30 mg/kg, p.o.) on extracellular levels of KYN, KYNA, 3-OH-KYN, AA and QA in the striatum (STR) of adult male WT mice either co-dosed ordosed independently is disclosed. Specifically, this experiment is aimed at demonstrating the différences in central KP métabolite élévations between Kynurenine dosing versus dosing a KMO inhibitor expected to block kynurenine catabolism downstream of KMO in an animal brain.
[0241] When microdialysis after PO dosing of kynurenine (30 mg/kg, p.o.), Compound 6 (30 mg/kg, p.o.), or kynurenine and Compound 6 co-dosed (30 mg/kg, p.o. each) was performed, it was shown that Compound 6 increases KYN (see FIG. 7), as well as protective métabolites KYNA (see FIG. 8) & AA (see FIG. 9) in mouse striatum, while kynurenine alone has little or no effect on these métabolites. Furthermore, PO administration of Compound 6 blocks toxic métabolites 3-OH-KYN (see FIG. 10) and QA (see FIG. 11), whereas kynurenine dosing increases them, due to kynurenine catabolism in mice brain.
[0242] While some embodiments hâve been shown and described, various modifications and substitutions may be made thereto without departing from the spirit and scope ofthe invention. For example, for claim construction purposes, it is not intended that the claims set forth hereinafter be construed in any way narrower than the literal language thereof, and it is thus not intended that exemplary embodiments from the spécification be read into the claims. Accordingly, it is to be understood that the présent invention has been described by way of illustration and not limitations on the scope ofthe claims.
Claims (92)
- What is claimed is:1. Use of a compound of Formula I:Formula I or a pharmaceutically acceptable sait thereof in the manufacture of a médicament for treating an HIV-related disorder in a subject infected with HIV, wherein the médicament is formulated for adjunctive administration with an antiviral agent and further whereinR1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C-Ca alkyl substituted with one substituent selected from C1-C4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo.
- 2. The use according to claim 1, wherein R1 is Ci-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent.
- 3. The use according to claim 2, wherein R1 is alkoxy.
- 4. The use according to claim 3, wherein R1 is sec-butoxy.
- 5. The use according to claim 4, wherein R1 is (R)-sec-butoxy.
- 6. The use according to claim 4, wherein R1 is (S)-sec-butoxy.
- 7. The use according to claim 3, wherein R1 is isopropoxy.
- 8. The use according to claim 2, wherein R1 is C1-C4 alkoxy substituted with one C3-C6 cycloalkyl substituent.
- 9. The use according to claim 8, wherein R1 is cyclopropylmethoxy.WO 2016/011316 PCT/US201S/040848
- 10. The use according to claim 1, wherein R1 is C1-C4 alkyl substituted with one substituent selected from C1-C4 alkoxy and C3-C6 cycloalkoxy.
- 11. The use according to claim 10, wherein R1 is C1-C4 alkyl substituted with one C1-C4 alkoxy substituent.
- 12. The use according to claim 11, wherein R1 is 1-methoxyethyl.
- 13. The use according to claim 11, wherein R1 is methoxymethyl.
- 14. The use according to claim 10, wherein R1 is C1-C4 alkyl substituted with one C3-C6 cycloalkoxy substituent.
- 15. The use according to claim 14, wherein R1 is 1-cyclopropoxyethyl.
- 16. The use according to claim 14, wherein R1 is cyclopropoxymethyl.
- 17. The use according to claim 1, wherein R1 is C3-C6 cycloalkoxy.
- 18. The use according to claim 17, wherein R1 is cyclobutoxy.
- 19. The use according to claim 17, wherein R1 is cyclopentyloxy.
- 20. The use according to claim 17, wherein R1 is cyclopropoxy.
- 21. The use according to claim 1, wherein R1 is halo.
- 22. The use according to claim 21, wherein R1 is chloro.
- 23. The use according to claim 21, wherein R1 is fluoro.
- 24. The use according to any one of claims 1 to 23, wherein R2 is selected from: C1-C4 alkoxy, C3-C6 cycloalkoxy, and halo.WO 2016/011316 PCT/US2015/040848
- 25. The use according to claim 24, wherein R2 is C1-C4 alkoxy.
- 26. The use according to claim 25, wherein R2 is isobutoxy.
- 27. The use according to claim 25, wherein R2 is isopropoxy.
- 28. The use according to claim 25, wherein R2 is methoxy.
- 29. The use according to claim 24, wherein R2 is C3-C6 cycloalkoxy.
- 30. The use according to claim 29, wherein R2 is cyclopropoxy.
- 31. The use according to claim 24, wherein R2 is halo.
- 32. The use according to claim 31, wherein R2 is chloro.
- 33. The use according to claim 31, wherein R2 is fluoro.
- 34. The use according to claim 1, wherein:R1 is selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C-1-C4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo; andR2 is selected from: C1-C4 alkoxy, C3-C6 cycloalkoxy, and halo.
- 35. The use according to claim 1, wherein:R1 is selected from sec-butoxy, chloro, cyclobutoxy, cyclopentyloxy, cyclopropoxy, 1-cyclopropoxyethyl, cyclopropylmethoxy, cyclopropoxymethyl, fluoro, methoxy, 1-methoxyethyl, and methoxymethyl; andR2 is selected from: chloro, cyclopropoxy, fluoro, isobutoxy, isopropoxy, and methoxy.
- 36. The use according to claim 1, wherein said compound of Formula I is selected from:6-(4-chloro-3-methoxyphenyl)pyrimidine-4-carboxylic acid;WO 2016/011316 PCT/US2015/0408486-(3-chloro-4-isopropoxyphenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-(cyclopentyloxy)phenyl)pyrimidine-4-carboxylic acid; (S)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid;(R)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-cyclobutoxyphenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-(cyclopropylmethoxy)phenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(methoxymethyl)phenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-(1-methoxyethyl)phenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(cyclopropoxymethyl)phenyl)pyrimidine-4-carboxylic acid; 6-(3-chloro-4-(1-cyclopropoxyethyl)phenyl)pyrimidine-4-carboxylic acid;6-(4-chloro-3-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid; 6-(4-chloro-3-isopropoxyphenyl)pyrimidine-4-carboxylic acid; 6-(4-chloro-3-fluorophenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-fluorophenyl)pyrimidine-4-carboxylic acid; 6-(3,4-dichlorophenyl)pyrimidine-4-carboxylic acid;6-(3,4-difluorophenyl)pyrimidine-4-carboxylic acid; and 6-(3-chloro-4-methoxy)pyrimidine-4-carboxylic acid.
- 37. The use according to any one of claims 1 to 36, wherein said médicament and said antiviral agent are: a) in admixture; b) chemically/physicochemically linked; c) chemically/physicochemically co-packaged; or d) unmixed but co-packaged orcopresented.
- 38. The use according to claim 37, wherein said médicament and said antiviral agent are copackaged in a single container or in a plurality of containers within a single outer package.
- 39. The use according to claim 37, wherein said médicament is administered before said antiviral agent.
- 40. The use according to claim 37, wherein said médicament is administered after said antiviral agent.WO 2016/011316 PCT/US2015/040848
- 41. The use according to claim 37, wherein said médicament and said antiviral agent are administered simultaneously.
- 42. The use according to claim 41, wherein the antiviral agent and the médicament are administered simultaneously in a unitary formulation.
- 43. The use according to claim 41, wherein the antiviral agent and the médicament are administered simultaneously in different formulations.
- 44. The use according to any one of claims 1 to 43, wherein said HIV is HIV-1.
- 45. The use according to claim 44, wherein said HIV is HIV-1 group M.
- 46. The use according to any one of claims 1 to 45, wherein said antiviral agent is selected from: entry inhibitors, fusion inhibitors, glycosidase inhibitors, CCR5 antagonists, immune-based thérapies, integrase inhibitors, maturation inhibitors, multi-class combination drugs, non-nucleoside reverse transcriptase inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors, pharmacokinetic enhancers, and protease inhibitors.
- 47. The use according to any one of claims 1 to 45, wherein said antiviral agent is selected from: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, CCR5 antagonists, and integrase strand transfer inhibitors, and combinations thereof.
- 48. The use according to any one of claims 1 to 45, wherein said antiviral agent is selected from: amdoxovir, Aptivus®, Aralen®, Atripla®, cenicriviroc, Cobicistat®, Combivir®, Complera®, Crixivan®, DermaVir®, Edurant®, elvitegravir, Emtriva®, Epivir®, Epzicom®, Fuzeon®, ibalizumab, Intelence®, interleukin-7, Invirase®, Isentress®, Kaletra®, lersivirine, lexgenleucel-T, Lexiva®, Norvir®, Plaquenil®, Proleukin®, Prezista®, PRO 140, Rescriptor®, Retrovir®, Reyataz®, SB-728-T, Selzentry®, SPI452, Stribild®, Sustiva®, tenofovir alafenamide fumarate, Tivicay®, Trii™, Trizivir®, Truvada®, Videx®, Videx® EC, Viracept®, Viramune®, Viramune® XR, Viread®, Zerit®, and Ziagen®.WO 2016/011316PCT/US2015/040848
- 49. The use according to any one of claims 1 to 45, wherein said antiviral agent is highly active antirétroviral therapy.
- 50. The use according to any one of claims 1 to 49, wherein said HIV-related disorder is a neurological disorder.
- 51. The use according to claim 50, wherein said neurological disorder is selected from: AIDS dementia complex, AIDS-induced encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis.
- 52. A composition comprising an antiviral agent and a compound of Formula I:Formula I or a pharmaceutically acceptable sait thereof;wherein:R1 and R2 are each independently selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C1-C4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycioalkoxy, and halo.
- 53. The composition according to claim 52, wherein R1 is C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent.
- 54. The composition according to claim 53, wherein R1 is C1-C4 alkoxy.
- 55. The composition according to claim 54, wherein R1 is sec-butoxy.
- 56. The composition according to claim 55, wherein R1 is (R)-sec-butoxy.WO 2016/011316 PCT/US2015/040848
- 57. The composition according to claim 55, wherein R1 is (S)-sec-butoxy.
- 58. The composition according to claim 54, wherein R1 is isopropoxy.
- 59. The composition according to claim 53, wherein R1 is C1-C4 alkoxy substituted with oneC3-C6 cycloalkyl substituent.
- 60. The composition according to claim 59, wherein R1 is cyclopropylmethoxy.
- 61. The composition according to claim 52 wherein R1 is C1-C4 alkyl substituted with one substituent selected from C1-C4 alkoxy and C3-C6 cycloalkoxy.
- 62. The composition according to claim 61, wherein R1 is C1-C4 alkyl substituted with one C1-C4 alkoxy substituent.
- 63. The composition according to claim 62, wherein R1 is 1-methoxyethyl.
- 64. The composition according to claim 62, wherein R1 is methoxymethyl.
- 65. The composition according to claim 61, wherein R1 is C1-C4 alkyl substituted with oneC3-C6 cycloalkoxy substituent.
- 66. The composition according to claim 65, wherein R1 is 1-cyclopropoxyethyl.
- 67. The composition according to claim 65, wherein R1 is cyclopropoxymethyl.
- 68. The composition according to claim 52, wherein R1 is C3-C6 cycloalkoxy.
- 69. The composition according to claim 68, wherein R1 is cyclobutoxy.
- 70. The composition according to claim 68, wherein R1 is cyclopentyloxy.
- 71. The composition according to claim 68, wherein R1 is cyclopropoxy.WO 2016/011316 PCT/US2015/040848
- 72. The composition according to claim 52, wherein R1 is halo.
- 73. The composition according to claim 72, wherein R1 is chloro.
- 74. The composition according to claim 72, wherein R1 is fluoro.
- 75. The composition according to any one of claims 52 to 74, wherein R2 is selected from:C1-C4 alkoxy, C3-C6 cycloalkoxy, and halo.
- 76. The composition according to claim 75, wherein R2 is C1-C4 alkoxy.
- 77. The composition according to claim 76, wherein R2 is isobutoxy.
- 78. The composition according to claim 76, wherein R2 is isopropoxy.
- 79. The composition according to claim 76, wherein R2 is methoxy.
- 80. The composition according to claim 75, wherein R2 is C3-Cs cycloalkoxy.
- 81. The composition according to claim 80, wherein R2 is cyclopropoxy.
- 82. The composition according to claim 75, wherein R2 is halo.
- 83. The composition according to claim 82, wherein R2 is chloro.
- 84. The composition according to claim 82, wherein R2 is fluoro.
- 85. The composition according to claim 52, wherein:R1 is selected from C1-C4 alkoxy optionally substituted with one C3-C6 cycloalkyl substituent, C1-C4 alkyl substituted with one substituent selected from C1-C4 alkoxy and C3-C6 cycloalkoxy, C3-C6 cycloalkoxy, and halo; andR2 is selected from: C1-C4 alkoxy, C3-C6 cycloalkoxy, and halo.WO 2016/011316 PCT/US2015/040848
- 86. The composition according to claim 52, wherein:R1 is selected from sec-butoxy, chloro, cyclobutoxy, cyclopentyloxy, cyclopropoxy, 1-cyclopropoxyethyl, cyclopropylmethoxy, cyclopropoxymethyl, fluoro, methoxy, 1-methoxyethyl, and methoxymethyl; andR2 is selected from: chloro, cyclopropoxy, fluoro, isobutoxy, isopropoxy, and methoxy.
- 87. The composition according to claim 52, wherein said compound of Formula I is selected from:6-(4-chloro-3-methoxyphenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-isopropoxyphenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(cyclopentyloxy)phenyl)pyrimidine-4-carboxylic acid;(S)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid;(R)-6-(4-sec-butoxy-3-chlorophenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-cyclobutoxyphenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(cyclopropylmethoxy)phenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(methoxymethyl)phenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(1-methoxyethyl)phenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(cyclopropoxymethyl)phenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-(1-cyclopropoxyethyl)phenyl)pyrimidine-4-carboxylic acid;6-(4-chloro-3-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid;6-(4-chloro-3-isopropoxyphenyl)pyrimidine-4-carboxylic acid;6-(4-chloro-3-isobutoxy-phenyl)pyrimidine-4-carboxylic acid;6-(4-chloro-3-fluorophenyl)pyrimidine-4-carboxylic acid;6-(3-chloro-4-fluorophenyl)pyrimidine-4-carboxylic acid;6-(3,4-dichlorophenyl)pyrimidine-4-carboxylic acid; 6-(3,4-difluorophenyl)pyrimidine-4-carboxylic acid; and 6-(3-chloro-4-methoxy)pyrimidine-4-carboxylic acid.
- 88. The composition according to any one of claims 52 to 87, comprising said antiviral agent and said compound of Formula I or a pharmaceutically acceptable sait thereof, in a copackaged drug product.WO 2016/011316 PCT/US2015/040848
- 89. The composition according to any one of claims 52 to 88, wherein said antiviral agent is selected from: entry inhibitors, fusion inhibitors, glycosidase inhibitors, CCR5 antagonists, immune-based thérapies, integrase inhibitors, maturation inhibitors, multiclass combination drugs, non-nucleoside reverse transcriptase inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors, pharmacokinetic enhancers, and protease inhibitors.
- 90. The composition according to any one of claims 52 to 88, wherein said antiviral agent is selected from: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, CCR5 antagonists, and integrase strand transfer inhibitors, and combinations thereof.
- 91. The composition according to any one of claims 52 to 88, wherein said antiviral agent is selected from: amdoxovir, Aptivus®, Aralen®, Atripla®, cenicriviroc, Cobicistat®, Combivir®, Complera®, Crixivan®, DermaVir®, Edurant®, elvitegravir, Emtriva®, Epivir®, Epzicom®, Fuzeon®, ibalizumab, Intelence®, interleukin-7, Invirase®, Isentress®, Kaletra®, lersivirine, lexgenleucel-T, Lexiva®, Norvir®, Plaquenil®, Proleukin®, Prezista®, PRO 140, Rescriptor®, Retrovir®, Reyataz®, SB-728-T, Selzentry®, SPI-452, Stribild®, Sustiva®, tenofovir alafenamide fumarate, Tivicay®, Trii™, Trizivir®, Truvada®, Videx®, Videx® EC, Viracept®, Viramune®, Viramune® XR, Viread®, Zerit®, and Ziagen®, and combinations thereof.
- 92. The composition according to any one of claims 52 to 88, wherein said antiviral agent is highly active antirétroviral therapy.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/025,840 | 2014-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18219A true OA18219A (en) | 2018-09-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3169684B1 (en) | Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders | |
JP6463366B2 (en) | 4-((2-Hydroxy-3-methoxybenzyl) amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors | |
JP2020532552A (en) | Compound having inhibitory and degrading activity of Bruton's tyrosine kinase Btk | |
EP3703680B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
JP5822840B2 (en) | Eye disease treatment | |
US11325896B2 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
JP2019529359A (en) | Beta-amino-isoquinolinylamide compounds | |
JPH04300834A (en) | Synergistic action of hiv reverse transcriptase inhibitor | |
WO2019079410A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
CN103739553A (en) | N-substituted imidazolecarboxylic acid ester chiral compound containing ether side chain, preparation method and application thereof | |
US20120022045A1 (en) | Bridged compounds as hiv integrase inhibitors | |
CA3042080A1 (en) | Ror-gamma modulators | |
EP3946390A1 (en) | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment | |
KR20090024257A (en) | 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors | |
AU2016309337A1 (en) | Hydroxytriazine compound and medical use thereof | |
EP3143005B1 (en) | Chemokine cxcr4 and ccr5 receptor modulators and used related thereto | |
US20230051850A1 (en) | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment | |
OA18219A (en) | Methods and compositions for HIV-related disorders. | |
CA3228265A1 (en) | Methods of treating migraine with mnk inhibitors | |
WO2019149734A1 (en) | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv | |
US20190112316A1 (en) | Thiazolo[3,2-a] pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy | |
JP2023503091A (en) | TRPV4 receptor ligand | |
CN110612290A (en) | Novel benzimidazolone compounds and medicinal use thereof | |
IL172935A (en) | Entry inhibitors of the hiv virus |